

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email editorial.bmjopen@bmj.com

BMJ Open


Post-marketing trials for novel drugs approved by both the FDA and EMA between 2005 and 2010: a cross-sectional study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-018587
Article Type:	Research
Date Submitted by the Author:	12-Jul-2017
Complete List of Authors:	Zeitoun, Jean-David; Hôtel Dieu Hospital, Epidémiologie Clinique; Saint-Antoine Hospital, Gastroenterology and Nutrition Ross, Joseph; Yale University School of Medicine, Internal Medicine Atal, Ignacio; Hotel Dieu Hospital, Epidémiologie Clinique Vivot, Alexandre; Hotel Dieu Hospital, Epidémiologie Clinique Downing, Nicholas; Brigham and Women's Hospital and Harvard Medical School, Medicine Baron, Gabriel; INSERM U1153; Hôtel Dieu Hospital, Centre d'Epidémiologie Clinique Ravaud, Philippe; Université Paris Descartes, Centre d'épidémiologie clinique; INSERM U1153
Primary Subject Heading:	Pharmacology and therapeutics
Secondary Subject Heading:	Research methods, Public health
Keywords:	THERAPEUTICS, STATISTICS & RESEARCH METHODS, EPIDEMIOLOGY

SCHOLARONE™
Manuscripts

1
2
3 **Post-marketing trials for novel drugs approved by both the FDA and EMA between**
4
5 **2005 and 2010: a cross-sectional study**
6
7

8 Jean-David Zeitoun, MD, MHPM, PhD candidate ^{1,2,3}, Joseph S. Ross, MD, MHS ^{4,5,6,7},
9
10 Ignacio Atal, MSc ^{1,8}, Alexandre Vivot ^{1,8}, Nicholas S. Downing, MD ⁹, Gabriel Baron, PhD
11
12 ^{1,8,10}, Philippe Ravaud, MD, PhD ^{1,8,10,11}
13

- 14
15 
- 16 1. Centre d'Épidémiologie Clinique, Hôpital Hôtel Dieu, Assistance Publique-Hôpitaux
17 de Paris, Paris, France
 - 18 2. Gastroenterology and Nutrition, Hôpital Saint-Antoine, Assistance Publiques-
19 Hôpitaux de Paris, Paris, France
 - 20 3. Proctology, Groupe Hospitalier Diaconesses-Croix Saint-Simon, Paris, France
 - 21 4. Department of Internal Medicine, Robert Wood Johnson Foundation Clinical Scholars
22 Program, Yale School of Medicine, New Haven, Connecticut, USA
 - 23 5. Department of Internal Medicine, Section of General Internal Medicine, Yale School
24 of Medicine, New Haven, Connecticut, USA
 - 25 6. Department of Health Policy and Management, Yale School of Public Health, New
26 Haven, Connecticut, USA
 - 27 7. Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New
28 Haven, Connecticut, USA
 - 29 8. INSERM UMR 1153, Centre de Recherche Épidémiologie et Statistique Paris
30 Sorbonne Cité (CRESS), METHODS Team, Paris, France
 - 31 9. Department of Medicine, Brigham and Women's Hospital and Harvard Medical
32 School, Boston, Massachusetts
 - 33 10. Université Paris Descartes, Sorbonne Paris Cité, Paris, France
 - 34 11. Department of Epidemiology, Columbia University Mailman School of Public Health,
35 New York, New York, United States of America.
- 36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Corresponding author:** Dr. Jean-David Zeitoun, MD, MHPM, PhD candidate, Centre
4
5 d'Epidémiologie Clinique, Hôpital Hôtel Dieu, Assistance Publique-Hôpitaux de Paris, Paris,
6
7 France. E-mail: jdzeitoun@yahoo.fr
8

9 **Word count:** 3520

10
11 **Abstract:** 300

12
13 **References:** 25

14
15 **Figures:** 3

16
17
18 **Tables:** 2
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

56 **ABSTRACT**
57
58
59
60

1
2
3 **Objectives:** To characterize post-marketing trials for drugs that were newly approved by the
4
5 U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
6
7

8 **Design and Setting:** Cross-sectional analysis of post-marketing trials registered in
9
10 ClinicalTrials.gov until September 2014 for all novel drugs approved by both regulators
11
12 between 2005 and 2010. Regulatory documents from both agencies were also used.
13
14

15 **Primary and secondary outcome measures:** All identified post-marketing trials were
16
17 classified according to the following features: planned enrolment, funding, status,
18
19 geographical location. We also determined whether trials studied the originally-approved
20
21 indication.
22
23

24
25 **Results:** There were 69 novel drugs approved between 2005 and 2010 that were eligible for
26
27 inclusion. A total of 6679 relevant post-marketing trials were identified. Median values of the
28
29 number of trials per drug was 55 (interquartile range [IQR]: 33-119) and of the number of
30
31 patients to be enrolled per trial was 60 (IQR, 28-183). Industry was the primary sponsor of
32
33 2713 trials (40.6%) and involved as a primary or secondary sponsor in 4176 trials (62.5%).
34
35 We found that 2901 trials (43.4%) were completed, 487 (7.3%) terminated, 1013 (15.2%)
36
37 were active yet not recruiting, 1895 (28.4%) recruiting, and 319 (4.8%) not yet recruiting.
38
39 Geographical data showed that 80% of post-marketing trials were conducted in only one
40
41 country and 84.4% of trials took place in Europe and (or) North America. We found that 2561
42
43 post-marketing trials (38.3%) studied another indication than the originally-approved
44
45 indication. Trials for which industry was a funder were less likely to assess the drug in
46
47 another indication (54.6% vs. 68.6%; $p < 0.0001$).
48
49
50
51

52 **Conclusions:** Post-marketing pharmaceutical research was found to be highly variable among
53
54 drugs, predominantly located in North America and Europe. Post-marketing trials were
55
56 frequently designed to study other indications than the originally-approved one. Although
57
58
59
60

1
2
3 some findings were reassuring, others question the lack of coordination of post-marketing
4
5 research.
6
7
8
9

10 11 **Strengths and limitations of this study** 12

13
14 This is the first study to systematically assess clinical trials performed after marketing
15 approval by the two leading regulators, namely the US Food and Drug Administration (FDA)
16 and the European Medicines Agency (EMA).
17
18
19

20
21 This approach allowed us to examine a substantial number of post-marketing trials over a
22 long time period.
23
24

25
26 However and due to registration bias, we cannot exclude that some true post-marketing trials
27 were missed and therefore unanalyzed.
28
29
30
31
32
33
34

35 **Funding:** This research received no specific grant from any funding agency in the public,
36 commercial or not-for-profit sectors.
37
38
39

40 **Competing interests:** Dr. Zeitoun reports that he serves as an advisor for several consulting
41 firms and communication companies linked with the pharmaceutical industry (Cepton, Oliver
42 Wyman, Roland Berger, McCann Healthcare, Omnicom, Grey Healthcare, Saatchi and
43 Saatchi Healthcare, Sudler& Hennessey, TBWA, inVentiv Health France, Havas). He also
44 reports compensation for lectures given to manufacturer professional associations;
45 collaboration with Mayoly-Spindler, Merck, Teva, Johnson & Johnson, and Menarini; unpaid
46 consultancy for EY; conducting workshops funded by Amgen; and being invited to a French
47 medical congress by AbbVie. Dr. Ross receives support through Yale University from
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Johnson and Johnson to develop methods of clinical trial data-sharing; from the Centers of
4
5 Medicare and Medicaid Services (CMS) to develop and maintain performance measures that
6
7 are used for public reporting; from Medtronic, Inc. and the US FDA to develop methods for
8
9 post-market surveillance of medical devices; from the Blue Cross Blue Shield Association to
10
11 better understand medical technology evaluation; and from the Laura and John Arnold
12
13 Foundation to support the Collaboration on Research Integrity and Transparency (CRIT) at
14
15 Yale.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are the two largest and most influential drug regulators worldwide. They tend to maintain similar premarket regulatory standards, and drug manufacturers likely submit the same evidence to both as part of the premarket application process. Drug evaluation continues after regulatory approval, in particular through post-authorization requirements and commitments. Yet these post-marketing clinical studies are limited in number and are not consistently completed. [1–3] This situation raises the question of whether other trials of these drugs after regulatory approval, including those conducted by industry and independent investigators, but not to fulfill regulatory requirements, should be considered part of ongoing, continuous evaluation efforts.

Post-marketing trials are designed with different intent than are premarket trials. Their designs are not systematically submitted to regulatory agencies before initiation because many post-marketing trials are conducted by independent investigators, and their conduct is less rigorously regulated. [4] Post-marketing trials seek to evaluate safety regarding rare events, to assess the real-life effectiveness of novel drugs and to measure their long-term effects. They also permit drug evaluation in different populations, other indications for the same disease, other diseases or with different delivery systems or dosage forms. Moreover, although premarket trials are nearly exclusively sponsored by the manufacturers, post-marketing trials can be funded by manufacturers but also academic or other types of non-profit institutions.

Nevertheless, post-marketing trials have considerable influence on all stakeholders, in particular researchers, practitioners and regulators or decision makers, because they provide cumulative evidence regarding marketed products. However, we lack an overall assessment of post-marketing trials regarding novel drugs. Post-marketing research has been studied for

1
2
3 high-risk devices [5] or even for drugs, but with a focused approach: safety [6,7] or given
4
5 therapeutic areas. [8–11] Some of those studies produced reassuring results, yet others showed
6
7 inconsistencies, with gaps in knowledge regarding some issues.
8
9

10
11 Our research objective was to provide a comprehensive description of post-marketing
12
13 trials registered in ClinicalTrials.gov, a publicly-accessible clinical trial registry maintained
14
15 by the US National Institutes of Health over almost a decade for a sample of drugs approved
16
17 by both the FDA and EMA from 2005 to 2010. We aimed to characterize the total number of
18
19 trials and patients studied, the geographical location of trials and their status (e.g., completed
20
21 or ongoing). We also sought to examine differences between the initial label and the specific
22
23 clinical condition studied in the post-marketing trials.
24
25
26
27
28
29

30 **Methods**

31 *Data sources and study sample*

32
33 We identified all novel drugs approved between January 1, 2005 and December 31, 2010 by
34
35 both the FDA and EMA through its Centralized Authorization Procedure. For the FDA,
36
37 Drugs@FDA is a publicly accessible database listing relevant regulatory actions for all
38
39 approved drugs. [12] For the EMA, information was accessible in the European Public
40
41 Assessment Reports, which provide a summary of scientific review and list notable regulatory
42
43 events for all drug submissions.[13] Studies of generic drugs, reformulations, combination
44
45 therapies and non-therapeutic agents such as radiographic dye were not included. This first
46
47 search led to a sample of 71 novel drugs approved by both regulators between 2005 and 2010.
48
49 Two drugs, everolimus and temsirolimus, were excluded because they were associated with
50
51 an abnormally high number of post-marketing trials involving drug-eluting stents.
52
53
54
55
56
57
58
59
60

Drug and manufacturer characteristics

The following data were retrieved for each drug: agent type (small molecule or biologic), dates of regulatory submissions for both the FDA and EMA, orphan status according to the FDA, orphan designation from the EMA, therapeutic class according to the Anatomical Therapeutic Chemical code, [14] initial label from both regulators, degree of novelty (first-in-class, advance-in-class, addition-to-class) as previously described in a paper from FDA officials [15] and size of the marketing-authorization holder (i.e., manufacturer). This latter information was obtained by personal communication with EMA officials (Dr. Constantinos Ziogas, Small and Medium-sized Manufacturer Office, EMA), who classified manufacturers as large pharmaceutical companies, intermediated-size companies or small- and medium-size companies according to the European Union definition based on headcount and financial turnover or balance sheet total.

Preapproval FDA pivotal trial characteristics

We obtained data for the expected length of treatment and number of patients from pivotal efficacy trials supporting FDA approvals that had been collected for a previous work. [16]

Post-marketing trials

On September 24, 2014, we extracted all trials that were registered at ClinicalTrials.gov for each drug of our sample, regardless of dates and other details. We then excluded trials with the following characteristics: included in the FDA regulatory submission (by a manual review of Drugs@FDA), with inadequate registered status (expanded-access trials, withdrawn trials, suspended trials), and mistakenly extracted (i.e., trials actually not assessing the drug of interest). We decided that all trials whose starting date had preceded the first regulatory submission (to the FDA or EMA) by 1 year or less would be classified as post-marketing trials. Trials that pertained to more than one drug in our sample were manually reviewed so as

1
2
3 to assign them to only one drug for the sake of further statistical analysis. Clinical judgment
4
5 was applied to choose the “leading” drug in each trial. When we could not determine the
6
7 leading drug, we used the following rules. If the trial was funded by a marketing-authorization
8
9 holder of one of the drugs, this drug was considered the leading drug. Otherwise, if the trial
10
11 involved a drug that was assessed for another indication than the originally approved
12
13 indication, this drug was considered the leading drug. Finally, when no leading drug could be
14
15 determined, the drug for which the last regulatory approval had been granted was considered
16
17 the drug tested and was classified as the leading drug.
18
19

20
21 For all remaining post-marketing trials, the following data were collected: condition
22
23 studied, starting date, study sponsors (as a primary sponsor or a collaborator), status at the
24
25 date of extraction (not yet recruiting, recruiting, active yet not recruiting, enrolling by
26
27 invitation, completed, terminated), number and list of countries, number of centers, trial
28
29 phase, study type (observational or interventional), randomization, and planned enrollment. In
30
31 addition, trials were classified as assessing the drug for its originally approved indication or
32
33 not, depending on the initial label. When the initial label differed between the FDA and EMA,
34
35 we accepted both labels as defining the originally approved indication. One of us (JDZ)
36
37 performed this classification after careful review of each primary label.
38
39

40 41 *Supplemental indications*

42
43 We also collected approvals of supplemental indications by the FDA during the study period
44
45 (2005-2014) by manual review of Drugs@FDA. In the “Approval date(s) and History,
46
47 Letters, Labels, Reviews” section, all events designated as “efficacy-new indication” or
48
49 “efficacy” were reviewed and retained if deemed appropriate. Labeling revision (such as those
50
51 related to a modified indication or an expanded patient population) and manufacturing change
52
53 or addition were not included, nor were irrelevant supplemental indications. We also aimed to
54
55 assess the average number of patients to be enrolled in post-marketing trials to gain approval
56
57
58
59
60

1
2
3 of a supplemental indication. For this purpose, we took into account all patients from all post-
4
5 marketing trials from the start of our sample through 1 year before the issuance of the
6
7 supplemental indication by the FDA.
8

9 10 *Statistical analysis*

11 Using descriptive statistics, we characterized the premarket characteristics of the novel drugs
12
13 included in our sample (drugs approved by both the FDA and EMA between 2005 and 2010).
14
15 Next, we used descriptive statistics to characterize features of all identified post-marketing
16
17 trials registered at ClinicalTrials.gov for all novel drugs. We used a series of trend charts
18
19 representing the annual number of post-marketing trials over the life-cycle of the drugs
20
21 according to off- and on-condition trials. All statistical tests were two-tailed, with a type I
22
23 error rate of 0.05. We used SAS 9.4 (SAS Institute; Cary, NC) for all statistical analyses.
24
25
26
27
28
29
30
31

32 **Results**

33 34 *Drug sample*

35
36 Our study sample included 69 novel drugs approved between 2005 and 2010 by both the FDA
37
38 and EMA. In all, 51 drugs (73.9%) were small molecules and 18 (26.1%) were biologics
39
40 (Table 1). The FDA had granted orphan status to 18 drugs (26.1%) and the EMA an orphan
41
42 designation to 20 (29.0%). Among these 69 novel drugs, 24 (34.8%) were first-in-class, 24
43
44 (34.8%) advance-in-class and 21 (30.4%) addition-to-class. The most prevalent therapeutic
45
46 category was antineoplastic and immunomodulating agents (29% of all novel drugs from the
47
48 sample) and many drugs (68.1%) were for chronic treatment. The manufacturer was a large
49
50 pharmaceutical company for 44 (63.8%) of the drugs. Other details are in Table 1.
51
52
53
54
55
56
57
58
59
60

1
2
3 *Number of post-marketing trials, status and patients recruited*
4
5

6 Sequential exclusions leading to our final study sample of 6679 relevant post-marketing trials
7 related to all 69 novel drugs are in Supplemental Material (S1). Characteristics of all post-
8 marketing trials are in Table 2. In all, 2901 trials (43.4%) were completed, 487 (7.3%)
9 terminated, 1013 (15.2%) active yet not recruiting, 1895 (28.4%) recruiting, and 319 (4.8%)
10 not yet recruiting. When comparing respective numbers of post-marketing trials and all
11 clinical trials (preapproval trials and post-marketing trials), the median proportion of post-
12 marketing trials per drug was 0.91 (interquartile range [IQR] 0.88-0.96). However, we found
13 high variability in number of post-marketing trials per drug, with a median of 55 trials per
14 drug (IQR, 33-119) and mean of 96.8 trials per drug (SD 110.3). Galsulfase, an orphan
15 medication indicated for Mucopolysaccharidosis VI, was associated with the lowest number
16 of post-marketing trials (n=3) and sorafenib, a tyrosine kinase inhibitor initially indicated for
17 kidney cancer, with the highest number of post-marketing trials (n=530).
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32

33 Planned enrollment was also highly variable, with trials only including one patient, and one
34 trial intending to recruit 904 585 patients (actually a prospective population-based cohort
35 study examining risk of congenital malformations after use of varenicline, a tobacco-use
36 cessation drug, in pregnant women). However, the median number of patients to be enrolled
37 per trial was 60 (IQR 28-183). Data on the total population to be enrolled in all post-
38 marketing trials for a given drug was also highly varied, with a median total sample of 15 418
39 patients (IQR 4932-37 523). Velaglucerase alfa, an orphan medication indicated for Gaucher
40 disease, was associated with the lowest population size to be included in trials (n=67), and
41 varenicline was associated with the greatest population to be enrolled (>1 million patients
42 overall). Supplemental Material (S2) shows the total number of patients to be included in
43 post-marketing trials for each drug and proportions of industry and non-industry funders.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Supplemental Material (S3) presents for each drug the number of patients included in
4
5 preapproval trials as compared with post-marketing trials. The median proportion for the
6
7 population recruited in post-marketing trials to the total population (i.e., preapproval samples
8
9 and post-marketing trials) was 0.92 (IQR 0.85-0.96). Again, alglucidase and velaglucerase
10
11 alfa were associated with the lowest number of patients in preapproval trials. In contrast, for
12
13 dabigatran, a drug initially indicated for preventing venous thromboembolism in the European
14
15 Union and to reduce the risk of stroke and systemic embolism in patients with non-valvular
16
17 atrial fibrillation in the United States, preapproval trials had recruited the highest number of
18
19 patients. The same figure also shows the proportions of patients enrolled in post-marketing
20
21 trials designed for the originally approved indication, another indication and both.
22
23

24 25 26 *Trial characteristics*

27
28
29 Data regarding study phases are shown in Table 2; only 18.6% of identified post-marketing
30
31 trials were considered phase IV trials, whereas the most prevalent category was phase II trials
32
33 (32.6%). Data regarding randomization were missing for 2452 post-marketing trials (36.7%).
34
35 Among the remaining trials for which these data were available, 3067 were randomized
36
37 (72.6%). Other data are in Table 2.
38
39

40 41 *Sponsor*

42
43
44 Industry funded or partially funded nearly two-thirds of post-marketing trials. Indeed, as
45
46 shown in Table 2, industry was the primary sponsor of 2713 trials (40.6%), but when also
47
48 considering manufacturers as minority funders, industry was involved in a total of 4176 trials
49
50 (62.5%). Data regarding post-marketing trials stratified by sponsorship are in Table 2. Figure
51
52 1 presents the drug sample with respect to the number of post-marketing trials and the
53
54 proportion of industry and non-industry funders for each drug. Supplemental Material (S4)
55
56 provides the same information but with a 4-year follow-up for each drug.
57
58
59
60

Conditions addressed in trials

Review of indications showed that 2441 post-marketing trials (36.5%) were launched for another indication than the originally approved indication. Figure 2 displays the number of non-approved indications studied in post-marketing trials for each drug of our sample, with information regarding the more advanced phase for each newly targeted indication. When comparing those trials with the total number of clinical trials (preapproval trials and post-marketing trials), we found a median proportion of 0.24 (IQR, 0.09-0.42). The median proportion for the population recruited in post-marketing trials designed for another indication than the originally approved indication to the total population from all clinical trials (preapproval trials and post-marketing trials) was 0.11 (IQR 0.03-0.30).

When analyzing the relationship between the trial sponsor and the trial indication, we found that trials for which industry was a sole or partial funder were less likely to assess the drug for another indication than the originally approved indication (54.6% of trials with industry funding vs 68.6% without industry funding; $p < 0.0001$). Findings regarding planned enrollment according to the indication and stratified on funding origin are in Supplemental Material (eTable). Regardless of the funder, post-marketing trials targeting originally approved indications planned to enroll more patients than those studying other indications.

Timing

The annual number of post-marketing trials over the life-cycle of drugs, stratified by indication, is shown in Figure 3, exhibiting an asymmetric bell pattern, with a rapid increase in number of post-marketing trials launched, a peak of activity within the third year after the first regulatory submission, then a progressive decline in number of launched trials. Detailed examination shows a greater proportion of trials designed for another indication than the originally approved indication at the beginning and end of drug life-cycles. Supplemental

1
2
3 Material (S5) is based on the same data but displays information regarding sponsors. Former
4
5 post-marketing trials were predominantly funded by industry versus academic or not-for-
6
7 profit entities and this proportion increased until the second year after the first regulatory
8
9 submission. Afterwards, the proportion of non-industry funders tended to increase over time.
10

11 12 *Location*

13
14
15 Overall, 80% of post-marketing trials were conducted in only one country. For 66 drugs, at
16
17 least one trial was conducted in at least two countries. Sorafenib was the most concerned drug
18
19 in this regard, with 74 trials involving at least two countries. Data regarding locations of trials
20
21 for each drug are in Supplemental Material (S6). In brief, post-marketing research was highly
22
23 concentrated in North America (i.e., United States and/or Canada; 44.8% of all post-
24
25 marketing trials of the sample) and Europe (25.0%). Post-marketing trials conducted in other
26
27 areas represented 15.6% of all trials, and trials conducted in multiple continents were few.
28

29
30
31 When examining the relation between trial location and study design with respect to the
32
33 original label, we found that trials from North America (United States and/or Canada) were
34
35 more frequently conducted for indications other than the originally approved indication versus
36
37 those located in Europe (50.4% v. 36.9%).
38

39 40 41 *Supplemental indications*

42
43
44 During the study period, 18 novel drugs (26.1%) were associated with a least a supplemental
45
46 indication by the FDA: one with 4 supplemental indications, one with 3 supplemental
47
48 indications, 5 with two supplemental indications and 11 with one supplemental indication.
49

50
51 The mean time between the first regulatory submission and subsequent supplemental
52
53 indication was 4.4 years (SD 1.7; IQR 3.3-5.7). The mean number of patients to be enrolled in
54
55 post-marketing trials before approval of a supplemental indication was 12763.1 (SD 12474.3;
56
57 IQR 3891.0-15856.0).
58
59
60

Discussion

In our study of post-marketing clinical research studies conducted for novel drugs approved by both the FDA and EMA between 2005 and 2010, we found high variability in number of post-marketing trials per drug and planned enrollment per trial. Indeed, the median planned enrollment was low, 60 patients, with a median of 55 trials per drug, most of which had not yet been completed at a minimum of 4 years after approval. Locations were concentrated, with 72.3% of post-marketing trials conducted in North America and/or Europe and 80% conducted in only one country. Approximately 40% of post-marketing trials were designed for an indication other than the originally approved one, more frequently concerning trials not involving industry funding. Overall, those findings reflect the lack of global coordination of post-marketing research for novel drugs.

Our study has several strengths. First, we focused on a sample of drugs approved by the two leading medical product regulators, FDA and EMA, which suggests that these drugs are likely to be of the greatest interest and importance to clinicians worldwide. Most previous studies focused on the FDA or EMA but rarely both. [16,17] Second, few comprehensive studies have analyzed post-marketing research despite its undisputed public health impact. Most research focused on safety or was limited to a given therapeutic area, or even only one drug. In addition, we chose a large study period, with a 6-year span for drug approvals, and nearly 10 years for the trial sample. Moreover, we followed a rigorous method for selecting post-marketing trials, excluding clinical trials included in the FDA submission, trials that had not been launched, trials mistakenly classified as involving the drug in ClinicalTrials.gov and trials whose starting date was too early as compared to regulatory submission. Third, we provide unique insights into the clinical research programs examining non-approved drug uses. Many studies have investigated off-label prescriptions, [18,19] but we used a slightly different approach. In effect, most drug labels are stringently phrased so as to be rigorously

1
2
3 aligned to pivotal trial criteria. [20] Therefore, categorizing trials according to the actual off-
4
5 or on-label status of the drug investigated would have led to classifying most as involving off-
6
7 label drug use. Put another way, the label was judged too narrow, and our method offers a
8
9 more significant picture for clinicians and epidemiologists. We believe that our classification
10
11 better reflects substantial evolution regarding the initially authorized use of novel drugs.
12
13

14
15 Our findings raise several issues worthy of consideration about post-marketing
16
17 research. First, we showed that post-marketing research is both a heterogeneous and
18
19 concentrated landscape, probably linked to its loose regulation [4] and to market forces.
20
21 Therefore, most initiatives are at the discretion of funders, either industry or academic
22
23 institutions, and driven by various factors not necessarily linked to medical need or relevancy.
24
25 The number of post-marketing trials per novel drug and planned enrollment were highly
26
27 variable, but most trials were conducted in only one country and North America and Europe
28
29 were by far the most frequent locations. Median planned enrollment was low and many trials
30
31 were still not completed at the time of data acquisition. These findings question the absence of
32
33 steering or the lack of effectiveness or incentive policies for post-marketing research. Second,
34
35 almost 40% of post-marketing trials were designed for an indication other than the originally
36
37 approved indication, with non-industry trials more likely concerned. Although industry has
38
39 been blamed for testing their products in a too-liberal manner, [21] our findings suggest that
40
41 academics and other non-industry bodies might be more prone to assess authorized drugs in
42
43 innovative ways to evaluate novel indications. Third, we found that post-marketing trials
44
45 designed for the originally approved indication planned to enroll a greater number of patients
46
47 on average than those targeting novel indications. This latter finding is somewhat reassuring
48
49 because post-marketing trials for an already approved indication aim to refine knowledge
50
51 regarding the long-term effect and/or safety and should therefore include more patients than
52
53 preapproval trials.
54
55
56
57
58
59
60

1
2
3 Our study has limitations. The first may be a registration bias at ClinicalTrials.gov,
4 which would alter the exhaustiveness of our assessment. Some trials are not registered by
5 researchers [22,23] and were therefore not included in our study. Others are imperfectly
6 registered, with some information missing. However, ClinicalTrials.gov is widely recognized
7 as a benchmark registry, and recent reports showed that compliance might have improved
8 over time. [24] Another limitation is the definition of post-marketing trials, in that clinical
9 trials are designed and launched according to a continuous timing and a single threshold
10 might be lacking for distinguishing pre- and post-marketing trials. Therefore, we decided to
11 consider trials starting at most 1 year before the first regulatory submission as post-marketing
12 trials even though we could have made another choice. A third limitation is related to data
13 sources. For some data, we relied on only one of the two selected regulators. We used such an
14 approach for the sake of convenience and recognize that this could be interpreted as a bias, yet
15 to our knowledge, there are very few if any differences in data between the two studied
16 regulators. Therefore, this latter limitation in the methods seems unlikely to affect our
17 findings.

18
19 In conclusion, our research shows that post-marketing research is highly variable and
20 concentrated, with on one hand, great differences in the number of post-marketing trials per
21 drug and in planned enrollment and on the other, most trials being conducted in only one
22 country, with North America and Europe the most represented locations. Approximately 40%
23 of post-marketing trials assessed the drug for an indication other than the originally approved
24 indication, more frequently non-industry trials. Even though some of our findings can be seen
25 as reassuring, others underline the lack of global coordination of post-marketing research for
26 novel drugs despite the undisputed influence of such research.

1
2
3 **Contributors:** Dr. Zeitoun and Pr. Ravaud were responsible for the conception and design of
4
5 this work. Dr. Zeitoun drafted the manuscript and was responsible for most of the data
6
7 acquisition. M. Ignacio Atal was responsible for data exportation and structuration. Dr.
8
9 Nicholas Downing was responsible for some of the data acquisition. Dr. Gabriel Baron
10
11 conducted the statistical analysis. Drs. Ross and Ravaud provided supervision. All authors
12
13 participated in the analysis and interpretation of the data and critically revised the manuscript
14
15 for important intellectual content.
16
17

18
19 **Data sharing statement:** Data files are available from the corresponding author on
20
21 reasonable request.
22
23

24 **Acknowledgements:** The authors are grateful to EMA officials who graciously helped them
25
26 classify drug manufacturers. They also thank Geoffroy Beraud-Chaulet for his useful work on
27
28 Drugs@FDA and Elise Diard for her invaluable help on figures.
29
30

31 32 **References**

- 33
34
35 1 United States Government Accountability Office. Drug Safety: FDA Expedites Many
36 Applications, But Data for Postapproval Oversight Need Improvement. 2015.
37 <http://www.gao.gov/products/GAO-16-192> (accessed 15 Nov 2016).
38
39 2 Fain K, Daubresse M, Alexander G. The food and drug administration amendments act
40 and postmarketing commitments. *JAMA* 2013;**310**:202–4. doi:10.1001/jama.2013.7900
41
42 3 Hoekman J, Klamer TT, Mantel-Teeuwisse AK, *et al.* Characteristics and follow-up of
43 postmarketing studies of conditionally authorized medicines in the EU. *Br J Clin*
44 *Pharmacol* 2016;**82**:213–26. doi:10.1111/bcp.12940
45
46 4 London AJ, Kimmelman J, Carlisle B. Research ethics. Rethinking research ethics: the
47 case of postmarketing trials. *Science* 2012;**336**:544–5. doi:10.1126/science.1216086
48
49 5 Rathi VK, Krumholz HM, Masoudi FA, *et al.* Characteristics of clinical studies conducted
50 over the total product life cycle of high-risk therapeutic medical devices receiving fda
51 premarket approval in 2010 and 2011. *JAMA* 2015;**314**:604–12.
52 doi:10.1001/jama.2015.8761
53
54 6 Reynolds RF, Lem JA, Gatto NM, *et al.* Is the large simple trial design used for
55 comparative, post-approval safety research? A review of a clinical trials registry and the
56
57
58
59
60

- 1
2
3 published literature. *Drug Saf* 2011;**34**:799–820. doi:10.2165/11593820-000000000-00000
- 4
5
6 7 Tang E, Ravaud P, Riveros C, *et al*. Comparison of serious adverse events posted at
7 ClinicalTrials.gov and published in corresponding journal articles. *BMC Med*
8 2015;**13**:189. doi:10.1186/s12916-015-0430-4
- 9
10 8 Bachert C, Maurer M. Safety and efficacy of desloratadine in subjects with seasonal
11 allergic rhinitis or chronic urticaria: results of four postmarketing surveillance studies.
12 *Clin Drug Investig* 2010;**30**:109–22. doi:10.2165/11530930-000000000-00000
- 13
14 9 Yeh RW, Kennedy K, Spertus JA, *et al*. Do postmarketing surveillance studies represent
15 real-world populations? A comparison of patient characteristics and outcomes after
16 carotid artery stenting. *Circulation* 2011;**123**:1384–90.
17 doi:10.1161/CIRCULATIONAHA.110.991075
- 18
19 10 Inrig JK, Califf RM, Tasneem A, *et al*. The landscape of clinical trials in nephrology: a
20 systematic review of Clinicaltrials.gov. *Am J Kidney Dis Off J Natl Kidney Found*
21 2014;**63**:771–80. doi:10.1053/j.ajkd.2013.10.043
- 22
23 11 Endrikat J, Vogtlaender K, Dohanish S, *et al*. Safety of Gadobutrol: Results From 42
24 Clinical Phase II to IV Studies and Postmarketing Surveillance After 29 Million
25 Applications. *Invest Radiol* 2016;**51**:537–43. doi:10.1097/RLI.0000000000000270
- 26
27 12 Drugs@FDA: FDA Approved Drug Products.
28 <http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm> (accessed 15 Nov 2016).
- 29
30 13 European Medicines Agency - Find medicine - European public assessment reports.
31 [http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&](http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d124)
32 [mid=WC0b01ac058001d124](http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d124) (accessed 15 Nov 2016).
- 33
34 14 World Health Organization (WHO) Collaborating Center for Drug Statistics
35 Methodology. ATC classification index with DDDs, 2014.
36 2014.http://www.whocc.no/atc_ddd_index/
- 37
38 15 Lanthier M, Miller KL, Nardinelli C, *et al*. An Improved Approach To Measuring Drug
39 Innovation Finds Steady Rates Of First-In-Class Pharmaceuticals, 1987–2011. *Health Aff*
40 (*Millwood*) 2013;**32**:1433–9. doi:10.1377/hlthaff.2012.0541
- 41
42 16 Downing NS, Aminawung JA, Shah ND, *et al*. Clinical trial evidence supporting FDA
43 approval of novel therapeutic agents, 2005-2012. *JAMA* 2014;**311**:368–77.
44 doi:10.1001/jama.2013.282034
- 45
46 17 Zeitoun J-D, Lefèvre JH, Downing NS, *et al*. Regulatory review time and post-market
47 safety events for novel medicines approved by the EMA between 2001 and 2010: a cross-
48 sectional study. *Br J Clin Pharmacol* 2015;**80**:716–26. doi:10.1111/bcp.12643
- 49
50 18 Eguale T, Buckeridge DL, Verma A, *et al*. Association of Off-label Drug Use and
51 Adverse Drug Events in an Adult Population. *JAMA Intern Med* 2016;**176**:55–63.
52 doi:10.1001/jamainternmed.2015.6058
- 53
54
55
56
57
58
59
60

- 1
2
3 19 Danés I, Agustí A, Vallano A, *et al.* Outcomes of off-label drug uses in hospitals: a
4 multicentric prospective study. *Eur J Clin Pharmacol* 2014;**70**:1385–93.
5 doi:10.1007/s00228-014-1746-2
6
- 7 20 Eichler H-G, Abadie E, Breckenridge A, *et al.* Bridging the efficacy-effectiveness gap: a
8 regulator’s perspective on addressing variability of drug response. *Nat Rev Drug Discov*
9 2011;**10**:495–506. doi:10.1038/nrd3501
10
- 11 21 Smith R, Gøtzsche PC, Groves T. Should journals stop publishing research funded by the
12 drug industry? *BMJ* 2014;**348**:g171.
13
- 14 22 Boccia S, Rothman KJ, Panic N, *et al.* Registration practices for observational studies on
15 ClinicalTrials.gov indicated low adherence. *J Clin Epidemiol* 2016;**70**:176–82.
16 doi:10.1016/j.jclinepi.2015.09.009
17
- 18 23 Dal-Ré R, Ross JS, Marušić A. Compliance with prospective trial registration guidance
19 remained low in high-impact journals and has implications for primary end point
20 reporting. *J Clin Epidemiol* 2016;**75**:100–7. doi:10.1016/j.jclinepi.2016.01.017
21
- 22 24 Viergever RF, Li K. Trends in global clinical trial registration: an analysis of numbers of
23 registered clinical trials in different parts of the world from 2004 to 2013. *BMJ Open*
24 2015;**5**:e008932. doi:10.1136/bmjopen-2015-008932
25
- 26 25 Lozano R, Naghavi M, Foreman K, *et al.* Global and regional mortality from 235 causes
27 of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden
28 of Disease Study 2010. *The Lancet* 2012;**380**:2095–128. doi:10.1016/S0140-
29 6736(12)61728-0
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Legends

Figure 1: Number of post-marketing trials and respective proportion of industry and non-industry funders.

Figure 2: Number of non-approved indications targeted in post-marketing trials for each drug of our study sample. Indications are rank-ordered on the basis of the number of post-marketing trials launched (from the greatest number of post-marketing trials on the left side of the figure to the lowest number on the right side). Color of boxes varies according to the advanced phase of the targeted indication. Indications are classified according to the Global Burden of Diseases classification. [25] Indications belonging to residual categories or health conditions not relevant to the Global Burden of Diseases were excluded and therefore are not represented in the Figure.

Figure 3: Annual number of post-marketing trials over the life-cycle of drugs, stratified by indication.

Supplemental File S1: Flow chart leading to the final study sample of 6679 relevant post-marketing trials.

Supplemental File S2: Total number of patients to be included in post-marketing trials for each drug.

Supplemental File S3: Population in preapproval trials and post-marketing trials.

Supplemental File S4: Number of post-marketing trials and respective proportion of industry and non-industry funders, with a 4-year follow-up for each drug.

1
2
3 Supplemental File S5: Annual number of post-marketing trials over the life-cycle of drugs,
4
5 stratified by sponsor.
6
7

8 Supplemental File S6: Locations of post-marketing trials.
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1. Characteristics of 69 novel drugs approved by both the FDA and EMA between 2005 and 2010 (excluding everolimus and temsirolimus).

Characteristics	n (%)
Agent type	
Small molecule	51 (73.9%)
Biologic	18 (26.1%)
Orphan status (FDA)	18 (26.1%)
Orphan designation (EMA)	20 (29.0%)
Therapeutic class according to the ATC code	
Alimentary tract and metabolism	10 (14.5%)
Anti-infectives for systemic use	12 (17.4%)
Antineoplastic and immunomodulating agents	20 (29.0%)
Blood and blood forming organs	5 (7.2%)
Cardiovascular system	5 (7.2%)
Nervous system	6 (8.7%)
Other*	11 (15.9%)
Degree of novelty (according to Lanthier <i>et al</i>)	
First-in-class	24 (34.8%)
Advance-in-class	24 (34.8%)
Addition-to-class	21 (30.4%)
Size of the marketing-authorization holder	
Large pharmaceutical company	44 (63.8%)
Intermediated-size company	23 (33.3%)
Small- and medium-size company	2 (2.9%)
Premarket evidence	
At least one pivotal trial using an active comparator	28 (40.6%)

Placebo only	34 (49.3%)
No comparator	7 (10.1%)
Total no. of included patients	
Min/max	18/18040
Median [Q1-Q3]	923 [324-1996]
Mean (SD)	1806 (2897)
Expected length of treatment	
Acute	8 (11.6%)
Intermediate	14 (20.3%)
Chronic	47 (68.1%)

ATC, Anatomical Therapeutic Chemical

*includes dermatological, genitourinary system and sex hormones, musculoskeletal system, sensory organs, systemic hormonal preparations, excluding sex hormones, and others

Table 2. Characteristics of industry and non-industry post-marketing trials registered at ClinicalTrials.gov before September 24, 2014 for the 69 novel drugs in the study sample.

Characteristics			Industry trials	Non-industry trials
Primary sponsor	Industry	2713 (40.6%)		
	NIH	286 (4.3%)		
	US Fed	15 (0.2%)		
	Other	3665 (54.9%)		
Industry involved either as a primary sponsor or a collaborator		4176 (62.5%)		
No. of post-marketing trials per drug	Min/max	3/530		
	Median [Q1-Q3]	55 [30-119]		
	Mean (SD)	96.8 (110.3)		
Population size per drug	Min/max	67/1.05E6		
	Median [Q1-Q3]	15418 [4932-37523]		
	Mean (SD)	62748 (166644)		

Therapeutic class according to the ATC code				
Alimentary tract and metabolism		832 (12.5%)	570 (68.5%)	262 (31.5%)
Anti-infectives for systemic use		828 (12.4%)	504 (60.9%)	324 (39.1%)
Antineoplastic and immunomodulating agents		3040 (45.5%)	1818 (59.8%)	1222 (40.2%)
Blood and blood forming organs		446 (6.7%)	277 (62.1%)	169 (37.9%)
Nervous system		485 (7.3%)	304 (62.7%)	181 (37.3%)
Other*		1048 (15.7%)	703 (67.1%)	345 (32.9%)
Trial design with respect to primary label	Another indication than the originally approved indication	2561 (38.3%)	1397 (54.5%)	1164 (45.5%)
	Originally approved indication	3889 (58.2%)	2666 (68.6%)	1223 (31.4%)
	Both the originally approved indication and another indication	229 (3.4%)	113 (49.3%)	116 (50.7%)
Study type	Observational	707 (10.6%)	468 (66.2%)	239 (33.8%)
	Interventional	5972 (89.4%)	3708 (62.1%)	2264 (37.9%)


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Randomization	Missing data	2452		
	Yes	3067 (72.6%)	1979 (64.5%)	1088 (35.5%)
	No	1160 (27.4%)	769 (66.3%)	391 (33.7%)
Study phase	0	34 (0.6%)	13 (38.2%)	21 (61.8%)
	I	933 (16.6%)	651 (69.8%)	282 (30.2%)
	I/II	423 (7.5%)	245 (58.0%)	178 (42.0%)
	II	1837 (32.6%)	1047 (57.0%)	790 (43.0%)
	II/III	109 (1.9%)	52 (47.7%)	57 (52.3%)
	III	1246 (22.1%)	1018 (81.7%)	228 (18.3%)
	IV	1045 (18.6%)	596 (57.0%)	449 (43.0%)
Centers	Missing data	503	428	75
	Min/max	1/1616	1/1616	1/922
	Median [Q1-Q3]	2 [1-12]	4 [1-23]	1 [1-2]
	Mean (SD)	19.9 (62.1)	26.4 (70.5)	9.8 (44.7)
Countries	Min/max	1/46	1/46	1/15
	Median [Q1-Q3]	1 [1-1]	1 [1-2]	1 [1-1]
	Mean (SD)	2.6 (4.7)	3.6 (5.8)	1.1 (0.7)


Planned enrollment	Min/max	1/904585	1/904585	1/61050
	Median [Q1-Q3]	60 [28-183]	72 [30-248]	48 [24-100]
	Mean (SD)	649.6 (12812)	943.8 (16167)	158.9 (1274.7)
Status at the time of data exportation	Not yet recruiting	319 (4.8%)	136 (42.6%)	183 (57.4%)
	Recruiting	1895 (28.4%)	886 (46.8%)	1009 (53.2%)
	Active, not recruiting	1013 (15.2%)	627 (61.9%)	386 (38.1%)
	Enrolling by invitation	64 (1.0%)	42 (65.6%)	22 (34.4%)
	Completed	2901 (43.4%)	2147 (74.0%)	754 (26.0%)
	Terminated	487 (7.3%)	338 (69.4%)	149 (30.6%)

NIH, US National Institutes of Health

*includes cardiovascular system, dermatological, genitourinary system and sex hormones, musculoskeletal system, sensory organs, systemic hormonal preparations, excluding sex hormones, and other




- Sorafenib
- Lenalidomide
- Ranibizumab
- Sunitinib
- Sitagliptin
- Raltegravir
- Lapatinib
- Varenicline
- Exenatide
- Dasatinib
- Tocilizumab
- Pazopanib
- Liraglutide
- Prasugrel
- Panitumumab
- Aliskiren
- Paliperidone
- Nilotinib
- Dabigatran
- Entecavir
- Abatacept
- Plerixafor
- Darunavir
- Maraviroc
- Saxagliptin
- Eltrombopag
- Ofatumumab
- Certolizumab pegol
- Methoxy polyethylene
- Ranolazine
- Deferasirox
- Denosumab
- Rotigotine
- Tolvaptan
- Degarelix
- Lacosamide
- Etravirine
- Ustekinumab
- Telbivudine
- Fesoterodine fumarate
- Eculizumab
- Golimumab
- Canakinumab
- Ambrisentan
- Sapropterin
- Micafungin
- Tigecycline
- Febuxostat
- Nepafenac
- Anidulafungin
- Posaconazole
- Tipranavir
- Collagenase clostridium
- Mecasermin
- Doripenem
- Romplostim
- Ulipristal
- Alglucidase
- Riloncept
- Silodosin
- Dronedarone
- Methylnaltrexone bromide
- Idursulfase
- Retapamulin
- Rufinamide
- Nelarabine
- Asenapine maleate
- Velaglycerase alfa
- Galsulfase




Industry trials
Non-industry trials

51
52
53
54
55
56
57
58
59
60

Phase :




1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




For peer review only


Figure 1. Sample construction of relevant post-marketing trials related to all 69 novel drugs both approved by the FDA and the EMA between 2005 and 2010, after exclusion of everolimus and temsirolimus



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Varenicline
Saxagliptin
Exenatide
Dabigatran
Abatacept
Prasugrel
Sitagliptin
Ranibizumab
Aliskiren
Sorafenib
Liraglutide
Lenalidomide
Lapatinib
Paliperidone
Micafungin
Entecavir
Darunavir
Certolizumab pegol
Sunitinib
Tocilizumab
Denosumab
Raltegravir
Lacosamide
Fesoterodine fumarate
Panitumumab
Methoxy polyethylene
Ustekinumab
Pazopanib
Tigecycline
Dasatinib
Golimumab
Silodosin
Febuxostat
Nilotinib
Canakinumab
Telbivudine
Tolvaptan
Plerixafor
Ambrisentan
Rotigotine
Maraviroc
Dronedarone
Degarelix
Ranolazine
Deferasirox
Ofatumumab
Nepafenac
Sapropterin
Eculizumab
Eltrombopag
Mecasermin
Ulipristal
Etravirine
Retapamulin
Posaconazole
Collagenase clostridium
Anidulafungin
Methylaltraxone bromide
Doripenem
Nelarabine
Rilonacept
Asenapine maleate
Romiplostim
Tipranavir
Rufinamide
Aglycidase
Idursulfase
Galsulfase
Velaglucerase alfa




Industry trials
Non-industry trials


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Population in preapproval trials


Population in post-marketing trials




1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Sorafenib
Lenalidomide
Ranibizumab
Sunitinib
Sitagliptin
Raltegravir
Lapatinib
Varenicline
Exenatide
Dasatinib
Tocilizumab
Pazopanib
Liraglutide
Prasugrel
Panitumumab
Aliskiren
Paliperidone
Nilotinib
Dabigatran
Entecavir
Abatacept
Plerixafor
Darunavir
Maraviroc
Saxagliptin
Eltrombopag
Ofatumumab
Certolizumab pegol
Methoxy polyethylene
Ranolazine
Deferasirox
Denosumab
Rotigotine
Tolvaptan
Degarelix
Lacosamide
Etravirine
Ustekinumab
Telbivudine
Fesoterodine fumarate
Eculizumab
Golimumab
Canakinumab
Ambrisentan
Sapropterin
Micafungin
Tigecycline
Febuxostat
Nepafenac
Anidulafungin
Posaconazole
Tipranavir
Collagenase clostridium
Mecasermin
Doripenem
Rompiplostim
Ulipristal
Alglucidase
Rilonacept
Silodosin
Dronedarone
Methylnaltrexone bromide
Idursulfase
Retapamulin
Rufinamide
Nelarabine
Asenapine maleate
Velaglycerase alfa
Galsulfase



Industry trials
Non-industry trials

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



eTable. Planned enrollment of post-marketing trials by industry and non-industry funding for indications targeted in trials.

Indication	Industry funding		Non-industry funding	
	No. of trials	Planned enrollment	No. of trials	Planned enrollment
Originally approved indication	2742	Median [Q1-Q3]: 100 [33-323] Mean (SD): 1322.0 (19921.8)	1251	Median [Q1-Q3]: 60 [29.5-150] Mean (SD): 230.9 (1771.2)
Other indication(s)	1310	Median [Q1-Q3]: 45 [24-128] Mean (SD): 167.7 (SD: 544.1)	1131	Median [Q1-Q3]: 40 [21-70] Mean (SD): 72.9 (148.0)
Both the originally approved indication and another indication	124	Median [Q1-Q3]: 60 [30-224] Mean (SD): 765.2 (2961.8)	121	Median [Q1-Q3]: 50 [30-120] Mean (SD): 218.1 (934.9)

Data were missing for 9 industry-funded trials and 5 other trials.

BMJ Open

Post-marketing studies for novel drugs approved by both the FDA and EMA between 2005 and 2010: a cross-sectional study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-018587.R1
Article Type:	Research
Date Submitted by the Author:	13-Sep-2017
Complete List of Authors:	Zeitoun, Jean-David; Hôtel Dieu Hospital, Epidémiologie Clinique; Saint-Antoine Hospital, Gastroenterology and Nutrition Ross, Joseph; Yale University School of Medicine, Internal Medicine Atal, Ignacio; Hotel Dieu Hospital, Epidémiologie Clinique Vivot, Alexandre; Hotel Dieu Hospital, Epidémiologie Clinique Downing, Nicholas; Brigham and Women's Hospital and Harvard Medical School, Medicine Baron, Gabriel; INSERM U1153; Hôtel Dieu Hospital, Centre d'Epidémiologie Clinique Ravaud, Philippe; Université Paris Descartes, Centre d'épidémiologie clinique; INSERM U1153
Primary Subject Heading:	Pharmacology and therapeutics
Secondary Subject Heading:	Research methods, Public health
Keywords:	THERAPEUTICS, STATISTICS & RESEARCH METHODS, EPIDEMIOLOGY

SCHOLARONE™
Manuscripts

1
2
3 **Post-marketing studies for novel drugs approved by both the FDA and EMA between**
4
5 **2005 and 2010: a cross-sectional study**
6
7

8 Jean-David Zeitoun, MD, MHPM, PhD candidate ^{1,2,3}, Joseph S. Ross, MD, MHS ^{4,5,6,7},
9
10 Ignacio Atal, MSc ^{1,8}, Alexandre Vivot, MD, MPH, ^{1,8}, Nicholas S. Downing, MD ⁹, Gabriel
11
12 Baron, PhD ^{1,8,10}, Philippe Ravaud, MD, PhD ^{1,8,10,11}
13

- 14
15
16 1. Centre d'Épidémiologie Clinique, Hôpital Hôtel Dieu, Assistance Publique-Hôpitaux
17 de Paris, Paris, France
18
19 2. Gastroenterology and Nutrition, Hôpital Saint-Antoine, Assistance Publiques-
20 Hôpitaux de Paris, Paris, France
21
22 3. Proctology, Groupe Hospitalier Diaconesses-Croix Saint-Simon, Paris, France
23
24 4. Department of Internal Medicine, Robert Wood Johnson Foundation Clinical Scholars
25 Program, Yale School of Medicine, New Haven, Connecticut, USA
26
27 5. Department of Internal Medicine, Section of General Internal Medicine, Yale School
28 of Medicine, New Haven, Connecticut, USA
29
30 6. Department of Health Policy and Management, Yale School of Public Health, New
31 Haven, Connecticut, USA
32
33 7. Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New
34 Haven, Connecticut, USA
35
36 8. INSERM UMR 1153, Centre de Recherche Épidémiologie et Statistique Paris
37 Sorbonne Cité (CRESS), METHODS Team, Paris, France
38
39 9. Department of Medicine, Brigham and Women's Hospital and Harvard Medical
40 School, Boston, Massachusetts
41
42 10. Université Paris Descartes, Sorbonne Paris Cité, Paris, France
43
44 11. Department of Epidemiology, Columbia University Mailman School of Public Health,
45 New York, New York, United States of America.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Corresponding author:** Dr. Jean-David Zeitoun, MD, MHPM, PhD candidate, Centre
4
5 d'Epidémiologie Clinique, Hôpital Hôtel Dieu, Assistance Publique-Hôpitaux de Paris, Paris,
6
7 France. E-mail: jdzeitoun@yahoo.fr
8

9 **Word count:** 3736

10
11 **Abstract:** 282

12
13 **References:** 29

14
15 **Figures:** 3

16
17
18 **Tables:** 2
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Objectives: To characterize post-marketing studies for drugs that were newly approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Design and Setting: Cross-sectional analysis of post-marketing studies registered in ClinicalTrials.gov until September 2014 for all novel drugs approved by both regulators between 2005 and 2010. Regulatory documents from both agencies were used.

Primary and secondary outcome measures: All identified post-marketing studies were classified according to planned enrolment, funding, status, and geographical location, and we determined whether studies studied the originally approved indication.

Results: Overall, 69 novel drugs approved between 2005 and 2010 were eligible for inclusion. A total of 6679 relevant post-marketing studies were identified; 5972 were interventional (89.4%). The median number of studies per drug was 55 (interquartile range [IQR]: 33-119) and median number of patients to be enrolled per study was 60 (IQR, 28-183). Industry was the primary sponsor of 2713 studies (40.6%) and was a primary or secondary sponsor in 4176 studies (62.5%). In all, 2901 studies (43.4%) were completed, 487 (7.3%) terminated, 1013 (15.2%) active yet not recruiting, 1895 (28.4%) recruiting, and 319 (4.8%) not yet recruiting. A total of 80% of studies were conducted in only one country and 84.4% took place in Europe and/or North America; 2561 (38.3%) studied another indication than the originally approved indication. Studies for which industry was a funder were less likely to assess the drug in another indication (54.6% vs. 68.6%; $p < 0.0001$).

Conclusions: Post-marketing pharmaceutical research was highly variable and predominantly located in North America and Europe. Post-marketing studies were frequently designed to study indications other than the originally approved one. Although some findings were reassuring, others question the lack of coordination of post-marketing research.

Strengths and limitations of this study

This is the first study to systematically assess clinical studies performed after marketing approval by the two leading regulators, namely the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

This approach allowed us to examine a substantial number of post-marketing studies over a long time period.

However and due to registration bias, we cannot exclude that some true post-marketing studies were missed and therefore unanalyzed.

Funding: This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests: Dr. Zeitoun reports that he serves as an advisor for several consulting firms and communication companies linked with the pharmaceutical industry (Cepton, Oliver Wyman, Roland Berger, McCann Healthcare, Omnicom, Grey Healthcare, Saatchi and Saatchi Healthcare, Sudler & Hennessey, TBWA, inVentiv Health France, Havas). He also reports compensation for lectures given to manufacturer professional associations; collaboration with Mayoly-Spindler, Merck, Teva, Johnson & Johnson, and Menarini; unpaid consultancy for EY; conducting workshops funded by Amgen; and being invited to a French medical congress by AbbVie. Dr. Ross receives support through Yale University from Johnson and Johnson to develop methods of clinical trial data-sharing; from the Centers of Medicare and Medicaid Services (CMS) to develop and maintain performance measures that are used for public reporting; from Medtronic, Inc. and the US FDA to develop methods for

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

post-market surveillance of medical devices; from the Blue Cross Blue Shield Association to better understand medical technology evaluation; and from the Laura and John Arnold Foundation to support the Collaboration on Research Integrity and Transparency (CRIT) at Yale.

For peer review only

Introduction

The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are the two largest and most influential drug regulators worldwide. They tend to maintain similar premarket regulatory standards, and drug manufacturers probably tend to submit the same evidence to both as part of the premarket application process, even though we lack comparative data. Drug evaluation continues after regulatory approval, in particular through post-authorization requirements and commitments. The US FDA can use several regulatory instruments and harness various sources for post-marketing evaluation of approved drugs. Among them are the FDA Adverse Reporting System and the Sentinel System. [1] The EMA also has a set of post-authorization measures, from direct request by its dedicated committee, to specific obligations for certain drugs, all aiming at retrieving data for post-marketing assessment.[2] Yet these post-marketing clinical studies required by regulators are limited in number and are not consistently completed. [3–5] This situation raises the question of whether other studies of these drugs after regulatory approval, including those conducted by industry and independent investigators, but not to fulfill regulatory requirements, should be considered part of ongoing, continuous evaluation efforts.

Post-marketing studies are designed with different intent than are premarket trials. Their designs are not systematically submitted to regulatory agencies before initiation because many post-marketing studies are conducted by independent investigators, and their conduct is less rigorously regulated. [6] Post-marketing studies seek to evaluate safety regarding rare events, to assess the real-life effectiveness of novel drugs and to measure their long-term effects. They also permit drug evaluation in different populations, other indications for the same disease, other diseases or with different delivery systems or dosage forms. Moreover, although premarket trials are nearly exclusively sponsored by the manufacturers, post-marketing studies can be funded by manufacturers but also academic or other types of non-

1
2
3 profit institutions. Some research also suggested that a substantial proportion of post-
4
5 marketing trials, even those with results eventually published in high-impact-factor journals,
6
7 were designed for marketing purposes rather than medical interest. [7,8]
8
9

10
11 Nevertheless, post-marketing studies have considerable influence on all stakeholders,
12
13 in particular researchers, practitioners and regulators or decision makers, because they provide
14
15 cumulative evidence regarding marketed products. However, we lack an overall assessment of
16
17 post-marketing studies regarding novel drugs. Post-marketing research has been studied for
18
19 high-risk devices [9] or even for drugs, but with a focused approach: safety [10,11] or given
20
21 therapeutic areas. [12–15] Some of those studies produced reassuring results, yet others
22
23 showed inconsistencies, with gaps in knowledge regarding some issues.
24
25

26
27 Our research objective was to provide a comprehensive description of post-marketing
28
29 studies registered in ClinicalTrials.gov, a publicly-accessible clinical trial registry maintained
30
31 by the US National Institutes of Health over almost a decade for a sample of drugs approved
32
33 by both the FDA and EMA from 2005 to 2010. We aimed to characterize the total number of
34
35 studies and patients studied, targeted indications, funding origin, geographical location of
36
37 studies and status (e.g., completed or ongoing). We also sought to examine differences
38
39 between the condition of the initial label and the specific clinical condition studied in the post-
40
41 marketing studies, to assess the influence of the sponsor on the targeted indication, and to
42
43 describe supplemental indications.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Methods

Data sources and study sample

We identified all novel drugs approved between January 1, 2005 and December 31, 2010 by both the FDA and EMA through its Centralized Authorization Procedure. For the FDA, Drugs@FDA is a publicly accessible database listing relevant regulatory actions for all approved drugs. [16] For the EMA, information was accessible in the European Public Assessment Reports, which provide a summary of scientific review and list notable regulatory events for all drug submissions.[17] Generic drugs, reformulations, combination therapies and non-therapeutic agents such as radiographic dye were not included. This first search led to a sample of 71 novel drugs approved by both regulators between 2005 and 2010. Two drugs, everolimus and temsirolimus, were excluded because they were associated with an abnormally high number of post-marketing studies involving drug-eluting stents.

Drug and manufacturer characteristics

The following data were retrieved for each drug: agent type (small molecule or biologic), dates of regulatory submissions for both the FDA and EMA, orphan status according to the FDA, orphan designation from the EMA, therapeutic class according to the Anatomical Therapeutic Chemical classification, [18] initial label from both regulators, degree of novelty (first-in-class, advance-in-class, addition-to-class) as previously described in a paper from FDA officials [19] and size of the marketing-authorization holder (i.e., manufacturer). This latter information was obtained by personal communication with EMA officials (Dr. Constantinos Ziogas, Small and Medium-sized Manufacturer Office, EMA), who classified manufacturers as large pharmaceutical companies, intermediated-size companies or small- and medium-size companies according to the European Union definition based on headcount and financial turnover or balance sheet total.

Preapproval FDA pivotal trial characteristics

We obtained data for the expected length of treatment and number of patients from pivotal efficacy trials supporting FDA approvals that had been collected for a previous work. [20] In brief, acute treatment was defined as expected use < 1 month, intermediate treatment as expected use from 1 month to 2 years, and chronic treatment as expected use > 2 years.

Post-marketing trials

On September 24, 2014, we extracted all studies that were registered at ClinicalTrials.gov for each drug of our sample, regardless of dates and other details. We then excluded studies with the following characteristics: included in the FDA regulatory submission (by a manual review of Drugs@FDA), with inadequate registered status (expanded-access studies, withdrawn studies, suspended studies), and mistakenly extracted (i.e., studies actually not assessing the drug of interest). We decided that all studies whose starting date had preceded the first regulatory submission (to the FDA or EMA) by 1 year or less would be classified as post-marketing studies. Trials that pertained to more than one drug in our sample were manually reviewed so as to assign them to only one drug for the sake of further statistical analysis. Clinical judgment was applied to choose the “leading” drug in each study. When we could not determine the leading drug, we used the following rules. If the study was funded by a marketing-authorization holder of one of the drugs, this drug was considered the leading drug. Otherwise, if the study involved a drug that was assessed for another indication than the originally approved indication, this drug was considered the leading drug. Finally, when no leading drug could be determined, the drug for which the last regulatory approval had been granted was considered the drug tested and was classified as the leading drug.

For all remaining post-marketing studies, the following data were collected: condition studied, starting date, study sponsors (as a primary sponsor or a collaborator), status at the

1
2
3 date of extraction (not yet recruiting, recruiting, active yet not recruiting, enrolling by
4 invitation, completed, terminated), number and list of countries, number of centers, study
5 phase, study type (observational or interventional), randomization, and planned enrollment. In
6 addition, studies were classified as assessing the drug for its originally approved indication or
7 not, depending on the initial label. When the initial label differed between the FDA and EMA,
8 we accepted both labels as defining the originally approved indication. One of us (JDZ)
9 performed this classification after careful review of each primary label.
10
11
12
13
14
15
16
17

18 *Supplemental indications*

19
20 We also collected approvals of supplemental indications by the FDA during the study period
21 (2005-2014) by manual review of Drugs@FDA. In the “Approval date(s) and History,
22 Letters, Labels, Reviews” section, all events designated as “efficacy-new indication” or
23 “efficacy” were reviewed and retained if deemed appropriate. Labeling revision (such as those
24 related to a modified indication or an expanded patient population) and manufacturing change
25 or addition were not included, nor were irrelevant supplemental indications. We also aimed to
26 assess the average number of patients to be enrolled in post-marketing studies to gain
27 approval of a supplemental indication. For this purpose, we took into account all patients from
28 all post-marketing studies from the start of our sample through 1 year before the issuance of
29 the supplemental indication by the FDA.
30
31
32
33
34
35
36
37
38
39
40
41
42

43 *Statistical analysis*

44
45 Using descriptive statistics, we characterized the premarket characteristics of the novel drugs
46 included in our sample (drugs approved by both the FDA and EMA between 2005 and 2010).
47
48 Next, we used descriptive statistics to characterize features of all identified post-marketing
49 studies registered at ClinicalTrials.gov for all novel drugs. We used a series of trend charts
50 representing the annual number of post-marketing studies over the life-cycle of the drugs
51
52
53
54
55
56
57
58
59
60

1
2
3 according to off- and on-condition studies. All statistical tests were two-tailed, with a type I
4 error rate of 0.05. We used SAS 9.4 (SAS Institute; Cary, NC) for all statistical analyses.
5
6
7

8 9 **Results**

10 *Drug sample*

11
12 Our study sample included 69 novel drugs approved between 2005 and 2010 by both the FDA
13 and EMA. In all, 51 drugs (73.9%) were small molecules and 18 (26.1%) were biologics
14 (Table 1). The FDA had granted orphan status to 18 drugs (26.1%) and the EMA an orphan
15 designation to 20 (29.0%). Among these 69 novel drugs, 24 (34.8%) were first-in-class, 24
16 (34.8%) advance-in-class and 21 (30.4%) addition-to-class. The most prevalent therapeutic
17 category was antineoplastic and immunomodulating agents (29% of all novel drugs from the
18 sample) and many drugs (68.1%) were for chronic treatment. The manufacturer was a large
19 pharmaceutical company for 44 (63.8%) of the drugs. Other details are in Table 1.
20
21
22
23
24
25
26
27
28
29
30
31

32 *Number of post-marketing trials, status and patients recruited*

33
34
35 Sequential exclusions leading to our final study sample of 6679 relevant post-marketing
36 studies related to all 69 novel drugs are in Supplemental Material (S1). Characteristics of all
37 post-marketing studies are in Table 2. In all, 2901 studies (43.4%) were completed, 487
38 (7.3%) terminated, 1013 (15.2%) active yet not recruiting, 1895 (28.4%) recruiting, and 319
39 (4.8%) not yet recruiting. When comparing respective numbers of post-marketing studies and
40 all clinical studies (preapproval pivotal trials and post-marketing studies), the median
41 proportion of post-marketing studies per drug was 0.91 (interquartile range [IQR] 0.88-0.96).
42
43 However, we found high variability in number of post-marketing studies per drug, with a
44 median of 55 studies per drug (IQR, 33-119) and mean of 96.8 studies per drug (SD 110.3).
45
46 Galsulfase, an orphan medication indicated for Mucopolysaccharidosis VI, was associated
47 with the lowest number of post-marketing studies (n=3) and sorafenib, a tyrosine kinase
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 inhibitor initially indicated for kidney cancer, with the highest number of post-marketing
4
5 studies (n=530).
6

7
8 Planned enrollment was also highly variable, with studies only including one patient, and one
9
10 study intending to recruit 904 585 patients (actually a prospective population-based cohort
11
12 study examining risk of congenital malformations after use of varenicline, a tobacco-use
13
14 cessation drug, in pregnant women). However, the median number of patients to be enrolled
15
16 per study was 60 (IQR 28-183). Data on the total population to be enrolled in all post-
17
18 marketing studies for a given drug was also highly varied, with a median total sample of
19
20 15 418 patients (IQR 4932-37 523). Velaglucerase alfa, an orphan medication indicated for
21
22 Gaucher disease, was associated with the lowest population size to be included in studies
23
24 (n=67), and varenicline was associated with the greatest population to be enrolled (>1 million
25
26 patients overall). Supplemental Material (S2) shows the total number of patients to be
27
28 included in post-marketing studies for each drug and proportions of industry and non-industry
29
30 funders.
31
32
33
34

35
36 Supplemental Material (S3) presents for each drug the number of patients included in
37
38 preapproval pivotal trials as compared with post-marketing studies. The median proportion
39
40 for the population recruited in post-marketing studies to the total population (i.e., preapproval
41
42 samples and post-marketing studies) was 0.92 (IQR 0.85-0.96). Again, alglucidase and
43
44 velaglucerase alfa were associated with the lowest number of patients in preapproval pivotal
45
46 trials. In contrast, for dabigatran, a drug initially indicated for preventing venous
47
48 thromboembolism in the European Union and to reduce the risk of stroke and systemic
49
50 embolism in patients with non-valvular atrial fibrillation in the United States, preapproval
51
52 pivotal trials had recruited the highest number of patients. The same figure also shows the
53
54 proportions of patients enrolled in post-marketing studies designed for the originally approved
55
56 indication, another indication and both.
57
58
59
60

Trial characteristics

Data regarding study phases are shown in Table 2; only 18.6% of identified post-marketing studies were considered phase IV studies, whereas the most prevalent category was phase II studies (32.6%). Data regarding randomization were missing for 2452 post-marketing studies (36.7%). Among the remaining studies for which these data were available, 3067 were randomized (72.6%). Other data are in Table 2.

Sponsor

Industry funded or partially funded nearly two-thirds of post-marketing studies. Indeed, as shown in Table 2, industry was the primary sponsor of 2713 studies (40.6%), but when also considering manufacturers as minority funders, industry was involved in a total of 4176 studies (62.5%). Data regarding post-marketing studies stratified by sponsorship are in Table 2. Figure 1 presents the drug sample with respect to the number of post-marketing studies and the proportion of industry and non-industry funders for each drug. Supplemental Material (S4) provides the same information but with a 4-year follow-up for each drug.

Conditions addressed in trials

Review of indications showed that 2441 post-marketing studies (36.5%) were launched for another indication than the originally approved indication. Figure 2 displays the number of non-approved indications studied in post-marketing studies for each drug of our sample, with information regarding the more advanced phase for each newly targeted indication. When comparing those studies with the total number of clinical studies (preapproval pivotal trials and post-marketing studies), we found a median proportion of 0.24 (IQR, 0.09-0.42). The median proportion for the population recruited in post-marketing studies designed for another indication than the originally approved indication to the total population from all clinical studies (preapproval pivotal trials and post-marketing studies) was 0.11 (IQR 0.03-0.30).

1
2
3 When analyzing the relationship between the study sponsor and the study indication, we
4
5 found that studies for which industry was a sole or partial funder were less likely to assess the
6
7 drug for another indication than the originally approved indication (54.6% of studies with
8
9 industry funding vs 68.6% without industry funding; $p < 0.0001$). Findings regarding planned
10
11 enrollment according to the indication and stratified on funding origin are in Supplemental
12
13 Material (eTable). Regardless of the funder, post-marketing studies targeting originally
14
15 approved indications planned to enroll more patients than those studying other indications.
16
17

18 19 *Timing*

20
21
22 The annual number of post-marketing studies over the life-cycle of drugs, stratified by
23
24 indication, is shown in Figure 3, exhibiting an asymmetric bell pattern, with a rapid increase
25
26 in number of post-marketing studies launched, a peak of activity within the third year after the
27
28 first regulatory submission, then a progressive decline in number of launched studies.
29

30
31 Detailed examination shows a greater proportion of studies designed for another indication
32
33 than the originally approved indication at the beginning and end of drug life-cycles.
34

35
36 Supplemental Material (S5) is based on the same data but displays information regarding
37
38 sponsors. Former post-marketing studies were predominantly funded by industry versus
39
40 academic or not-for-profit entities and this proportion increased until the second year after the
41
42 first regulatory submission. Afterwards, the proportion of non-industry funders tended to
43
44 increase over time.
45

46 47 *Location*

48
49
50 Overall, 80% of post-marketing studies were conducted in only one country. For 66 drugs, at
51
52 least one study was conducted in at least two countries. Sorafenib was the most concerned
53
54 drug in this regard, with 74 studies involving at least two countries. Data regarding locations
55
56 of studies for each drug are in Supplemental Material (S6). In brief, post-marketing research
57
58
59
60

1
2
3 was highly concentrated in North America (i.e., United States and/or Canada; 44.8% of all
4 post-marketing studies of the sample) and Europe (25.0%). Post-marketing studies conducted
5 in other areas represented 15.6% of all studies, and studies conducted in multiple continents
6 were few. When examining the relation between study location and study design with respect
7 to the original label, we found that studies from North America (United States and/or Canada)
8 were more frequently conducted for indications other than the originally approved indication
9 versus those located in Europe (50.4% v. 36.9%).
10
11
12
13
14
15
16
17
18

19 *Supplemental indications*

20
21
22 During the study period, 18 novel drugs (26.1%) were associated with a least a supplemental
23 indication by the FDA: one with 4 supplemental indications, one with 3 supplemental
24 indications, 5 with two supplemental indications and 11 with one supplemental indication.
25
26
27
28

29 The mean time between the first regulatory submission and subsequent supplemental
30 indication was 4.4 years (SD 1.7; IQR 3.3-5.7). The mean number of patients to be enrolled in
31 post-marketing studies before approval of a supplemental indication was 12763.1 (SD
32 12474.3; IQR 3891.0-15856.0).
33
34
35
36
37
38

39 **Discussion**

40
41 In our study of post-marketing clinical research studies conducted for novel drugs approved
42 by both the FDA and EMA between 2005 and 2010, we found high variability in number of
43 post-marketing studies per drug and planned enrollment per study. Indeed, the median
44 planned enrollment was low, 60 patients, with a median of 55 studies per drug, most of which
45 had not yet been completed at a minimum of 4 years after approval. Locations were
46 concentrated, with 72.3% of post-marketing studies conducted in North America and/or
47 Europe and 80% conducted in only one country. Approximately 40% of post-marketing
48 studies were designed for an indication other than the originally approved one, more
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 frequently concerning studies not involving industry funding. Overall, those findings reflect
4
5 the lack of global coordination of post-marketing research for novel drugs.
6
7

8 Our study has several strengths. First, we focused on a sample of drugs approved by
9
10 the two leading medical product regulators, FDA and EMA, which suggests that these drugs
11
12 are likely to be of the greatest interest and importance to clinicians worldwide. Most previous
13
14 studies focused on the FDA or EMA but rarely both. [20,21] Second, few comprehensive
15
16 studies have analyzed post-marketing research despite its undisputed public health impact. [9–
17
18 14] Most research focused on safety or was limited to a given therapeutic area, or even only
19
20 one drug. In addition, we chose a large study period, with a 6-year span for drug approvals,
21
22 and more than 10 years for the trial sample. Moreover, we followed a rigorous method for
23
24 selecting post-marketing studies, excluding clinical trials included in the FDA submission,
25
26 studies that had not been launched, studies mistakenly classified as involving the drug in
27
28 ClinicalTrials.gov and studies whose starting date was too early as compared to regulatory
29
30 submission. Third, we provide unique insights into the clinical research programs examining
31
32 non-approved drug uses. Many studies have investigated off-label prescriptions, [22,23] but
33
34 we used a slightly different approach. In effect, most drug labels are stringently phrased so as
35
36 to be rigorously aligned to pivotal trial criteria. [24] Therefore, categorizing studies according
37
38 to the actual off- or on-label status of the drug investigated would have led to classifying most
39
40 as involving off-label drug use. Put another way, the label was judged too narrow, and our
41
42 method offers a more significant picture for clinicians and epidemiologists. We believe that
43
44 our classification better reflects substantial evolution regarding the initially authorized use of
45
46 novel drugs.
47
48
49
50
51
52

53 Our findings raise several issues worthy of consideration about post-marketing
54
55 research. First, we showed that post-marketing research is both a heterogeneous and
56
57 concentrated landscape, probably linked to its loose regulation [6] and to market forces.
58
59
60

1
2
3 Therefore, most initiatives are at the discretion of funders, either industry or academic
4
5 institutions, and driven by various factors not necessarily linked to medical need or relevancy.
6
7 For instance, prior research has shown that many post-marketing trials were “seeding trials”,
8
9 designed for marketing purposes rather than scientific relevancy. [7,8] The number of post-
10
11 marketing studies per novel drug and planned enrollment were highly variable, but most
12
13 studies were conducted in only one country and North America and Europe were by far the
14
15 most frequent locations. Median planned enrollment was low and many studies were still not
16
17 completed at the time of data acquisition. These findings question the absence of steering or
18
19 the lack of effectiveness or incentive policies for post-marketing research. Second, almost
20
21 40% of post-marketing studies were designed for an indication other than the originally
22
23 approved indication, with non-industry trials more likely concerned. Although industry has
24
25 been blamed for testing their products in a too-liberal manner, [25] our findings suggest that
26
27 academics and other non-industry bodies might be more prone to assess authorized drugs in
28
29 innovative ways to evaluate novel indications. Third, we found that post-marketing studies
30
31 designed for the originally approved indication planned to enroll a greater number of patients
32
33 on average than those targeting novel indications. This latter finding is somewhat reassuring
34
35 because post-marketing studies for an already approved indication aim to refine knowledge
36
37 regarding the long-term effect and/or safety and should therefore include more patients than
38
39 preapproval pivotal trials.
40
41
42
43
44

45
46 Our study has limitations. The first may be a registration bias at ClinicalTrials.gov,
47
48 which would alter the exhaustiveness of our assessment. Some studies are not registered by
49
50 researchers [26,27] and were therefore not included in our study. Others are imperfectly
51
52 registered, with some information missing. However, ClinicalTrials.gov is widely recognized
53
54 as a benchmark registry, and recent reports showed that compliance might have improved
55
56 over time. [28] Another limitation is the definition of post-marketing studies, in that clinical
57
58
59
60

1
2
3 studies are designed and launched according to a continuous timing and a single threshold
4
5 might be lacking for distinguishing pre- and post-marketing trials. Therefore, we decided to
6
7 consider studies starting at most 1 year before the first regulatory submission as post-
8
9 marketing studies even though we could have made another choice. A third limitation is
10
11 related to data sources. For some data, we relied on only one of the two selected regulators.
12
13 We used such an approach for the sake of convenience and recognize that this could be
14
15 interpreted as a bias, yet to our knowledge, there are very few if any differences in data
16
17 between the two studied regulators. Therefore, this latter limitation in the methods seems
18
19 unlikely to affect our findings. Finally, we could not identify whether post-marketing trials
20
21 were relevant or useful because we did not analyze their design, endpoints, or comparators,
22
23 among other factors.
24
25
26

27
28 In conclusion, our research shows that post-marketing research is highly variable and
29
30 concentrated, with on one hand, great differences in the number of post-marketing studies per
31
32 drug and in planned enrollment and on the other, most studies being conducted in only one
33
34 country, with North America and Europe the most represented locations. Approximately 40%
35
36 of post-marketing studies assessed the drug for an indication other than the originally
37
38 approved indication, more frequently non-industry studies. Even though some of our findings
39
40 can be seen as reassuring, others underline the lack of global coordination of post-marketing
41
42 research for novel drugs despite the undisputed influence of such research.
43
44
45
46
47
48

49 **Contributors:** Dr. Zeitoun and Pr. Ravaud were responsible for the conception and design of
50
51 this work. Dr. Zeitoun drafted the manuscript and was responsible for most of the data
52
53 acquisition. M. Ignacio Atal was responsible for data exportation and structuration. Dr.
54
55 Nicholas Downing was responsible for some of the data acquisition. Dr. Gabriel Baron
56
57
58
59
60

1
2
3 conducted the statistical analysis. Drs. Ross and Ravaud provided supervision. All authors
4 participated in the analysis and interpretation of the data and critically revised the manuscript
5 for important intellectual content.
6
7
8

9
10 **Data sharing statement:** Data files are available from the corresponding author on
11 reasonable request.
12
13

14
15 **Acknowledgements:** The authors are grateful to EMA officials who graciously helped them
16 classify drug manufacturers. They also thank Geoffroy Beraud-Chaulet for his useful work on
17 Drugs@FDA and Elise Diard for her invaluable help on figures.
18
19
20
21

22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

References

1 Ball R, Robb M, Anderson S, *et al.* The FDA's sentinel initiative—A comprehensive
2 approach to medical product surveillance. *Clin Pharmacol Ther* 2016;**99**:265–8.

3 doi:10.1002/cpt.320

4 European Medicines Agency. Post-authorisation procedural Q&A - Post-authorisation
5 measures: questions and answers.

6 [http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/q_and_a/q_and_a_detail_000](http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/q_and_a/q_and_a_detail_000037.jsp)
7 037.jsp (accessed 8 Sep 2017).

8 United States Government Accountability Office. Drug Safety: FDA Expedites Many
9 Applications, But Data for Postapproval Oversight Need Improvement. 2015.

10 <http://www.gao.gov/products/GAO-16-192> (accessed 15 Nov 2016).

11 Fain K, Daubresse M, Alexander G. The food and drug administration amendments
12 act and postmarketing commitments. *JAMA* 2013;**310**:202–4. doi:10.1001/jama.2013.7900

1
2
3 5 Hoekman J, Klamer TT, Mantel-Teeuwisse AK, *et al.* Characteristics and follow-up of
4 postmarketing studies of conditionally authorized medicines in the EU. *Br J Clin Pharmacol*
5 2016;**82**:213–26. doi:10.1111/bcp.12940
6
7
8

9
10 6 London AJ, Kimmelman J, Carlisle B. Research ethics. Rethinking research ethics: the
11 case of postmarketing trials. *Science* 2012;**336**:544–5. doi:10.1126/science.1216086
12
13

14
15 7 Alexander GC. Seeding trials and the subordination of science. *Arch Intern Med*
16 2011;**171**:1107–8. doi:10.1001/archinternmed.2011.232
17
18

19
20 8 Barbour V, Burch D, Godlee F, *et al.* Characterisation of trials where marketing
21 purposes have been influential in study design: a descriptive study. *Trials* 2016;**17**:31.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 13 Yeh RW, Kennedy K, Spertus JA, *et al.* Do postmarketing surveillance studies
4 represent real-world populations? A comparison of patient characteristics and outcomes after
5 carotid artery stenting. *Circulation* 2011;**123**:1384–90.
6
7 doi:10.1161/CIRCULATIONAHA.110.991075
8
9
10
11
12 14 Inrig JK, Califf RM, Tasneem A, *et al.* The landscape of clinical trials in nephrology:
13 a systematic review of Clinicaltrials.gov. *Am J Kidney Dis Off J Natl Kidney Found*
14 2014;**63**:771–80. doi:10.1053/j.ajkd.2013.10.043
15
16
17
18
19 15 Endrikat J, Vogtlaender K, Dohanish S, *et al.* Safety of Gadobutrol: Results From 42
20 Clinical Phase II to IV Studies and Postmarketing Surveillance After 29 Million Applications.
21
22 *Invest Radiol* 2016;**51**:537–43. doi:10.1097/RLI.0000000000000270
23
24
25
26
27 16 Drugs@FDA: FDA Approved Drug Products.
28
29 <http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm> (accessed 15 Nov 2016).
30
31
32 17 European Medicines Agency - Find medicine - European public assessment reports.
33
34 [http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid](http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d124)
35 [=WC0b01ac058001d124](http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d124) (accessed 15 Nov 2016).
36
37
38
39 18 World Health Organization (WHO) Collaborating Center for Drug Statistics
40
41 Methodology. ATC classification index with DDDs, 2014.
42
43 2014.http://www.whocc.no/atc_ddd_index/
44
45
46
47 19 Lanthier M, Miller KL, Nardinelli C, *et al.* An Improved Approach To Measuring
48
49 Drug Innovation Finds Steady Rates Of First-In-Class Pharmaceuticals, 1987–2011. *Health*
50
51 *Aff (Millwood)* 2013;**32**:1433–9. doi:10.1377/hlthaff.2012.0541
52
53
54
55
56
57
58
59
60

1
2
3 20 Downing NS, Aminawung JA, Shah ND, *et al.* Clinical trial evidence supporting FDA
4 approval of novel therapeutic agents, 2005-2012. *JAMA* 2014;**311**:368–77.

5
6
7 doi:10.1001/jama.2013.282034

8
9
10 21 Zeitoun J-D, Lefèvre JH, Downing NS, *et al.* Regulatory review time and post-market
11 safety events for novel medicines approved by the EMA between 2001 and 2010: a cross-
12 sectional study. *Br J Clin Pharmacol* 2015;**80**:716–26. doi:10.1111/bcp.12643

13
14
15 22 Eguale T, Buckeridge DL, Verma A, *et al.* Association of Off-label Drug Use and
16 Adverse Drug Events in an Adult Population. *JAMA Intern Med* 2016;**176**:55–63.

17
18
19
20
21
22 doi:10.1001/jamainternmed.2015.6058

23
24
25 23 Danés I, Agustí A, Vallano A, *et al.* Outcomes of off-label drug uses in hospitals: a
26 multicentric prospective study. *Eur J Clin Pharmacol* 2014;**70**:1385–93. doi:10.1007/s00228-
27 014-1746-2

28
29
30
31
32 24 Eichler H-G, Abadie E, Breckenridge A, *et al.* Bridging the efficacy-effectiveness gap:
33 a regulator's perspective on addressing variability of drug response. *Nat Rev Drug Discov*
34 2011;**10**:495–506. doi:10.1038/nrd3501

35
36
37
38
39 25 Smith R, Gøtzsche PC, Groves T. Should journals stop publishing research funded by
40 the drug industry? *BMJ* 2014;**348**:g171.

41
42
43
44
45 26 Boccia S, Rothman KJ, Panic N, *et al.* Registration practices for observational studies
46 on ClinicalTrials.gov indicated low adherence. *J Clin Epidemiol* 2016;**70**:176–82.

47
48
49
50
51
52 doi:10.1016/j.jclinepi.2015.09.009

53 27 Dal-Ré R, Ross JS, Marušić A. Compliance with prospective trial registration
54 guidance remained low in high-impact journals and has implications for primary end point
55 reporting. *J Clin Epidemiol* 2016;**75**:100–7. doi:10.1016/j.jclinepi.2016.01.017

1
2
3 28 Viergever RF, Li K. Trends in global clinical trial registration: an analysis of numbers
4 of registered clinical trials in different parts of the world from 2004 to 2013. *BMJ Open*
5 2015;**5**:e008932. doi:10.1136/bmjopen-2015-008932
6
7
8

9
10 29 Lozano R, Naghavi M, Foreman K, *et al*. Global and regional mortality from 235
11 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global
12 Burden of Disease Study 2010. *The Lancet* 2012;**380**:2095–128. doi:10.1016/S0140-
13 6736(12)61728-0
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Legends

Figure 1: Number of post-marketing studies and respective proportion of industry and non-industry funders.

Figure 2: Number of non-approved indications targeted in post-marketing studies for each drug of our study sample. Indications are rank-ordered on the basis of the number of post-marketing studies launched (from the greatest number of post-marketing studies on the left side of the figure to the lowest number on the right side). Color of boxes varies according to the advanced phase of the targeted indication. Indications are classified according to the Global Burden of Diseases classification. [29] Indications belonging to residual categories or health conditions not relevant to the Global Burden of Diseases were excluded and therefore are not represented in the Figure.

Figure 3: Annual number of post-marketing studies over the life-cycle of drugs, stratified by indication.

Supplemental File S1: Flow chart leading to the final study sample of 6679 relevant post-marketing studies.

Supplemental File S2: Total number of patients to be included in post-marketing studies for each drug.

Supplemental File S3: Population in preapproval pivotal trials and post-marketing studies.

Supplemental File S4: Number of post-marketing studies and respective proportion of industry and non-industry funders, with a 4-year follow-up for each drug.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Supplemental File S5: Annual number of post-marketing studies over the life-cycle of drugs, stratified by sponsor.

Supplemental File S6: Locations of post-marketing studies.

Supplemental File S7: Data from S2, S3 and S6, presented as tables.

For peer review only

Table 1. Characteristics of 69 novel drugs approved by both the FDA and EMA between 2005 and 2010 (excluding everolimus and temsirolimus).

Characteristics	n (%)
Agent type	
Small molecule	51 (73.9%)
Biologic	18 (26.1%)
Orphan status (FDA)	18 (26.1%)
Orphan designation (EMA)	20 (29.0%)
Accelerated approval (FDA)	14 (20.3%)
Therapeutic class according to the ATC classification	
Alimentary tract and metabolism	10 (14.5%)
Anti-infectives for systemic use	12 (17.4%)
Antineoplastic and immunomodulating agents	20 (29.0%)
Blood and blood forming organs	5 (7.2%)
Cardiovascular system	5 (7.2%)
Nervous system	6 (8.7%)
Other*	11 (15.9%)
Degree of novelty (according to Lanthier <i>et al</i>)	
First-in-class	24 (34.8%)
Advance-in-class	24 (34.8%)
Addition-to-class	21 (30.4%)
Size of the marketing-authorization holder	
Large pharmaceutical company	44 (63.8%)
Intermediated-size company	23 (33.3%)
Small- and medium-size company	2 (2.9%)
Premarket evidence	

Total no. of included patients	
Min/max	18/18040
Median [Q1-Q3]	923 [324-1996]
Mean (SD)	1806 (2897)
Expected length of treatment	
Acute	8 (11.6%)
Intermediate	14 (20.3%)
Chronic	47 (68.1%)

ATC, Anatomical Therapeutic Chemical

*includes dermatological, genitourinary system and sex hormones, musculoskeletal system, sensory organs, systemic hormonal preparations, excluding sex hormones, and others

Table 2. Characteristics of industry and non-industry post-marketing studies registered at ClinicalTrials.gov before September 24, 2014 for the 69 novel drugs in the study sample.

Characteristics			Industry studies	Non-industry studies
Primary sponsor	Industry	2713 (40.6%)		
	NIH	286 (4.3%)		
	US Fed	15 (0.2%)		
	Other	3665 (54.9%)		
Industry involved either as a primary sponsor or a collaborator		4176 (62.5%)		
No. of post-marketing studies per drug	Min/max	3/530		
	Median [Q1-Q3]	55 [30-119]		
	Mean (SD)	96.8 (110.3)		
Population size per drug	Min/max	67/1.05E6		
	Median [Q1-Q3]	15418 [4932-37523]		
	Mean (SD)	62748 (166644)		

Therapeutic class according to the ATC				
Alimentary tract and metabolism		832 (12.5%)	570 (68.5%)	262 (31.5%)
Anti-infectives for systemic use		828 (12.4%)	504 (60.9%)	324 (39.1%)
Antineoplastic and immunomodulating agents		3040 (45.5%)	1818 (59.8%)	1222 (40.2%)
Blood and blood forming organs		446 (6.7%)	277 (62.1%)	169 (37.9%)
Nervous system		485 (7.3%)	304 (62.7%)	181 (37.3%)
Other*		1048 (15.7%)	703 (67.1%)	345 (32.9%)
Study design with respect to primary label	Another indication than the originally approved indication	2561 (38.3%)	1397 (54.5%)	1164 (45.5%)
	Originally approved indication	3889 (58.2%)	2666 (68.6%)	1223 (31.4%)
	Both the originally approved indication and another indication	229 (3.4%)	113 (49.3%)	116 (50.7%)
Study type	Observational	707 (10.6%)	468 (66.2%)	239 (33.8%)
	Interventional	5972 (89.4%)	3708 (62.1%)	2264 (37.9%)

Randomization	Missing data	2452		
	Yes	3067 (72.6%)	1979 (64.5%)	1088 (35.5%)
	No	1160 (27.4%)	769 (66.3%)	391 (33.7%)
Study phase	0	34 (0.6%)	13 (38.2%)	21 (61.8%)
	I	933 (16.6%)	651 (69.8%)	282 (30.2%)
	I/II	423 (7.5%)	245 (58.0%)	178 (42.0%)
	II	1837 (32.6%)	1047 (57.0%)	790 (43.0%)
	II/III	109 (1.9%)	52 (47.7%)	57 (52.3%)
	III	1246 (22.1%)	1018 (81.7%)	228 (18.3%)
	IV	1045 (18.6%)	596 (57.0%)	449 (43.0%)
Centers	Missing data	503	428	75
	Min/max	1/1616	1/1616	1/922
	Median [Q1-Q3]	2 [1-12]	4 [1-23]	1 [1-2]
	Mean (SD)	19.9 (62.1)	26.4 (70.5)	9.8 (44.7)
Countries	Min/max	1/46	1/46	1/15
	Median [Q1-Q3]	1 [1-1]	1 [1-2]	1 [1-1]
	Mean (SD)	2.6 (4.7)	3.6 (5.8)	1.1 (0.7)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Planned enrollment	Min/max	1/904585	1/904585	1/61050
	Median [Q1-Q3]	60 [28-183]	72 [30-248]	48 [24-100]
	Mean (SD)	649.6 (12812)	943.8 (16167)	158.9 (1274.7)
Status at the time of data exportation	Not yet recruiting	319 (4.8%)	136 (42.6%)	183 (57.4%)
	Recruiting	1895 (28.4%)	886 (46.8%)	1009 (53.2%)
	Active, not recruiting	1013 (15.2%)	627 (61.9%)	386 (38.1%)
	Enrolling by invitation	64 (1.0%)	42 (65.6%)	22 (34.4%)
	Completed	2901 (43.4%)	2147 (74.0%)	754 (26.0%)
	Terminated	487 (7.3%)	338 (69.4%)	149 (30.6%)

NIH, US National Institutes of Health

*includes cardiovascular system, dermatological, genitourinary system and sex hormones, musculoskeletal system, sensory organs, systemic hormonal preparations, excluding sex hormones, and other




Figure 1

179x153mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2

215x279mm (300 x 300 DPI)





Figure 3


105x51mm (300 x 300 DPI)

For review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


Supplemental Material 1. Sample construction of relevant post-marketing trials related to all 69 novel drugs both approved by the FDA and the EMA between 2005 and 2010, after exclusion of everolimus and temsirolimus







165x133mm (300 x 300 DPI)

For peer review only



179x153mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27



Supplemental file S2 bis: Total number of patients to be included in post-marketing studies for each drug

Drug	Total number of patients to be included in post-marketing studies	Percentage of industry funders	Percentage of non-industry funders
Varenicline	1045002	90.8	9.2
Saxagliptin	785853	99.6	0.4
Exenatide	420256	99.3	0.7
Dabigatran	368063	93.1	6.9
Abatacept	240227	99.6	0.4
Prasugrel	128744	66.9	33.1
Sitagliptin	113824	91.8	8.2
Ranibizumab	89765	81.9	18.1
Aliskiren	76864	96.6	3.4
Sorafenib	76434	66.2	33.8
Liraglutide	73106	92.0	8.0
Lenalidomide	60805	62.8	37.2
Lapatinib	45881	77.4	22.6
Paliperidone	43024	92.6	7.4
Micafungin	41363	95.0	5.0
Entecavir	39787	65.5	34.5
Darunavir	39773	94.7	5.3
Certolizumab pegol	37523	91.6	8.4
Sunitinib	37320	70.7	29.3
Tocilizumab	36262	91.8	8.2
Denosumab	32688	90.2	9.8
Raltegravir	31285	60.8	39.2
Lacosamide	30236	93.9	6.1
Fesoterodine fumarate	23699	97.2	2.8
Panitumumab	22585	66.9	33.1
Methoxy polyethylene	22102	99.2	0.8
Ustekinumab	20873	95.5	4.5
Pazopanib	19332	54.1	45.9
Tigecycline	19322	89.3	10.7
Dasatinib	19320	72.2	27.8
Golimumab	18801	90.1	9.9
Silodosin	17591	97.5	2.5
Febuxostat	16330	88.8	11.2
Nilotinib	15657	77.0	23.0
Canakinumab	15418	98.2	1.8
Telbivudine	13590	55.6	44.4
Tolvaptan	13552	89.7	10.3
Plerixafor	13450	84.6	15.4
Ambrisentan	12300	46.1	53.9

Drug	Total number of patients to be included in post-marketing studies	Percentage of industry funders	Percentage of non-industry funders
Rotigotine	12258	96.8	3.2
Maraviroc	11957	74.3	25.7
Dronedarone	10947	62.7	37.3
Degarelix	10811	93.0	7.0
Ranolazine	10614	69.8	30.2
Deferasirox	8812	86.4	13.6
Ofatumumab	7988	84.0	16.0
Nepafenac	7627	86.2	13.8
Sapropterin	6328	90.3	9.7
Eculizumab	6065	95.5	4.5
Eltrombopag	5590	85.2	14.8
Mecasermin	5291	88.5	11.5
Ulipristal	4932	90.9	9.1
Etravirine	4881	46.4	53.6
Retapamulin	4819	95.6	4.4
Posaconazole	4391	65.1	34.9
Collagenase clostridium	3897	91.2	8.8
Anidulafungin	3819	70.8	29.2
Methylnaltrexone bromide	3581	96.6	3.4
Doripenem	3204	87.3	12.7
Nelarabine	3104	15.6	84.4
Rilonacept	2790	84.1	15.9
Asenapine maleate	2179	100.0	0.0
Romiplostim	1627	95.1	4.9
Tipranavir	1401	98.9	1.1
Rufinamide	1174	76.3	23.7
Alglucidase	803	61.4	38.6
Idursulfase	408	80.4	19.6
Galsulfase	269	100.0	0.0
Velaglucerase alfa	67	100.0	0.0

Supplemental file S3 bis: Population in preapproval pivotal trials and post-marketing studies

Drug	Population in preapproval pivotal trials	Population in post-marketing studies			Total
		Another indication	Originally-approved indication	Both in originally approved indication and in other(s) indication	
Dabigatran	18040	10896	332151	25016	368063
Prasugrel	13457	1960	126669	115	128744
Denosumab	7808	15825	16863	0	32688
Aliskiren	5663	20625	56239	0	76864
Dronedarone	4604	20	10927	0	10947
Varenicline	4198	1847	1024229	18926	1045002
Tocilizumab	4190	2201	34061	0	36262
Saxagliptin	4148	396	785457	0	785853
Febuxostat	4101	854	15476	0	16330
Liraglutide	3978	9509	62587	1010	73106
Ulipristal	3754	4012	920	0	4932
Tigecycline	2758	1339	6291	11692	19322
Methoxy polyethylene	2398	8	22094	0	22102
Golimumab	2297	1222	17579	0	18801
Asenapine maleate	2294	0	2179	0	2179
Sitagliptin	2220	2794	110745	285	113824
Doripenem	2117	267	2937	0	3204
Ustekinumab	1996	3793	17080	0	20873
Fesoterodine fumarate	1935	182	23517	0	23699
Entecavir	1814	0	39787	0	39787
Paliperidone	1665	2548	35755	4721	43024
Micafungin	1643	1105	39983	275	41363
Ranolazine	1593	2945	5773	1896	10614
Exenatide	1446	2810	417301	145	420256
Abatacept	1382	5622	234605	0	240227
Telbivudine	1367	0	13590	0	13590
Lacosamide	1308	1133	29103	0	30236
Etravirine	1203	0	4881	0	4881
Posaconazole	1202	1949	1282	1160	4391
Rotigotine	1163	4067	7671	520	12258
Tipranavir	1159	0	1365	36	1401
Ranibizumab	1139	20541	36906	32318	89765
Rufinamide	1097	288	886	0	1174
Certolizumab pegol	1088	1200	33077	3246	37523
Sildenafil	923	1339	16252	0	17591
Anidulafungin	857	792	2993	34	3819
Sorafenib	769	54317	18809	3308	76434
Raltegravir	699	83	31202	0	31285
Nepafenac	688	815	6812	0	7627
Darunavir	637	0	39773	0	39773

Drug	Population in preapproval pivotal trials	Population in post-marketing studies			Total
		Another indication	Originally-approved indication	Both in originally approved indication and in other(s) indication	
Plerixafor	623	1467	11644	339	13450
Degarelix	610	791	10020	0	10811
Deferasirox	586	153	8609	50	8812
Dasatinib	565	9267	9090	963	19320
Sunitinib	481	16462	18362	2496	37320
Panitumumab	461	5197	16874	514	22585
Maraviroc	448	560	11397	0	11957
Pazopanib	435	10363	8060	909	19332
Tolvaptan	418	12221	356	975	13552
Ambrisentan	393	715	11585	0	12300
Collagenase clostridium	374	3897	0	0	3897
Lapatinib	324	7678	37714	489	45881
Methylnaltrexone bromide	321	1359	2222	0	3581
Eltrombopag	232	2957	2533	100	5590
Retapamulin	210	267	4417	135	4819
Nilotinib	196	2431	8531	4695	15657
Lenalidomide	193	19105	39873	1827	60805
Nelarabine	190	35	3069	0	3104
Ofatumumab	154	3076	2595	2317	7988
Romiplostim	125	543	1084	0	1627
Idursulfase	96	0	408	0	408
Sapropterin	88	1133	5195	0	6328
Eculizumab	87	3861	2204	0	6065
Mecasermin	70	623	4668	0	5291
Riloncept	47	2765	25	0	2790
Galsulfase	39	0	269	0	269
Canakinumab	31	15157	261	0	15418
Velaglucerase alfa	25	0	67	0	67
Alglucidase	18	0	803	0	803

Supplemental file S6 bis: Location of post-marketing studies (sample size by location)

	Location						
	North America	Europa	Others	North America + Europa	North America + Others	Europa + Others	North America + Europa + Others
Abatacept	2267	2801	1575	1255	1715	0	9390
Alglucidase	633	5	0	83	22	20	40
Aliskiren	8269	3870	5760	5467	975	3097	33667
Ambrisentan	2128	6116	196	64	524	0	2330
Anidulafungin	1115	225	214	0	282	21	776
Asenapine maleate	950	0	0	0	0		0
Canakinumab	164	320	34	1037	0	274	13569
Certolizumab pegol	7278	5383	2401	3225	271	0	6265
Collagenase clostridium	1402	541	79	0	1286	0	400
Dabigatran	272415	47930	9639	636	0	7096	21220
Darunavir	755	2880	4076	12	1213	576	2940
Dasatinib	7476	2941	1139	768	195	484	5866
Deferasirox	1473	1023	1148	0	0	2506	2575
Degarelix	1613	5646	1522	783	0	0	1147
Denosumab	1168	4547	2692	427	0	1439	16134
Doripenem	82	195	818	52	0	0	1911
Dronedarone	480	4143	279	0	0	556	5436
Eculizumab	4683	447	52	60	92	80	463
Eltrombopag	1486	458	992	82	0	100	1059
Entecavir	807	1096	21848	4	200	184	14460
Etravirine	857	1730	570	30	671	279	536
Exenatide	371779	5876	10283	736	3323	2963	25151
Febuxostat	5473	0	1424	0	7500	0	744
Fesoterodine fumarate	4555	1231	2245	0	0	794	8210

	Location						
	North America	Europa	Others	North America + Europa	North America + Others	Europa + Others	North America + Europa + Others
Galsulfase	10	0	0	0	200	0	59
Golimumab	5459	5031	1361	706	11	120	811
Idursulfase	0	0	81	79	0	108	118
Lacosamide	1597	4167	946	1210	0	0	3281
Lapatinib	5446	9359	2989	502	1106	876	22398
Lenalidomide	22422	19825	1874	1804	1916	1972	8846
Liraglutide	15787	12960	13865	717	0	415	26892
Maraviroc	1268	1849	561	129	876	186	5698
Mecasermin	2073	3198	0	0	0	0	0
Methoxy polyethylene	340	13375	4841	0	0	2828	718
Methylnaltrexone bromide	1968	31	0	0	0	0	1462
Micafungin	37521	664	1518	0	84	619	836
Nelarabine	95	720	13	0	36	40	1900
Nepafenac	5927	227	1021	0	0	0	0
Nilotinib	1660	4393	1964	175	512	218	2882
Ofatumumab	2401	1549	20	60	14	122	3294
Paliperidone	4400	1064	10125	0	838	4753	11816
Panitumumab	2888	8858	164	375	0	0	1700
Pazopanib	5947	5436	2684	374	207	102	4518
Plerixafor	2374	850	164	0	61	46	0
Posaconazole	154	1370	126	96	0	0	600
Prasugrel	23597	42550	7015	4760	17372	0	26550
Raltegravir	3106	4949	8048	366	3156	1173	4308
Ranibizumab	17679	20576	9883	694	232	3832	33851
Ranolazine	4524	551	310	0	0	0	5102

	Location						
	North America	Europa	Others	North America + Europa	North America + Others	Europa + Others	North America + Europa + Others
Retapamulin	784	0	3000	0	508	465	60
Rilonacept	1242	30	0	0	0	244	1274
Romiplostim	280	119	76	63	62	0	175
Rotigotine	2229	3696	2553	220	601	2197	371
Rufinamide	230	278	366	75	0	0	0
Sapropterin	5120	1018	0	0	190	0	0
Saxagliptin	166072	594	13757	0	501	2670	21205
Silodosin	885	1196	1559	0	0	0	0
Sitagliptin	5577	2079	12049	164	804	3770	21728
Sorafenib	17405	13223	17312	973	2681	3230	20954
Sunitinib	8448	7676	2806	2557	2006	167	10074
Telbivudine	159	132	8934	0	308	367	1790
Tigecycline	473	1987	9632	0	1175	473	1588
Tipranavir	71	504	0	0	246	0	84
Tocilizumab	2511	17868	4033	1054	228	1270	9070
Tolvaptan	1227	304	3131	0	1300	0	4500
Ulipristal	855	2845	51	579	60	542	0
Ustekinumab	2823	2649	2004	166	0	1290	9859
Varenicline	34574	67592	6523	1307	360	0	18706
Velaglycerase alfa	0	50	17	0	0	0	0

eTable. Planned enrollment of post-marketing trials by industry and non-industry funding for indications targeted in trials.

Indication	Industry funding		Non-industry funding	
	No. of trials	Planned enrollment	No. of trials	Planned enrollment
Originally approved indication	2742	Median [Q1-Q3]: 100 [33-323] Mean (SD): 1322.0 (19921.8)	1251	Median [Q1-Q3]: 60 [29.5-150] Mean (SD): 230.9 (1771.2)
Other indication(s)	1310	Median [Q1-Q3]: 45 [24-128] Mean (SD): 167.7 (SD: 544.1)	1131	Median [Q1-Q3]: 40 [21-70] Mean (SD): 72.9 (148.0)
Both the originally approved indication and another indication	124	Median [Q1-Q3]: 60 [30-224] Mean (SD): 765.2 (2961.8)	121	Median [Q1-Q3]: 50 [30-120] Mean (SD): 218.1 (934.9)

Data were missing for 9 industry-funded trials and 5 other trials.

BMJ Open


Post-marketing studies for novel drugs approved by both the FDA and EMA between 2005 and 2010: a cross-sectional study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-018587.R2
Article Type:	Research
Date Submitted by the Author:	03-Nov-2017
Complete List of Authors:	Zeitoun, Jean-David; Hôtel Dieu Hospital, Epidémiologie Clinique; Saint-Antoine Hospital, Gastroenterology and Nutrition Ross, Joseph; Yale University School of Medicine, Internal Medicine Atal, Ignacio; Hotel Dieu Hospital, Epidémiologie Clinique Vivot, Alexandre; Hotel Dieu Hospital, Epidémiologie Clinique Downing, Nicholas; Brigham and Women's Hospital and Harvard Medical School, Medicine Baron, Gabriel; INSERM U1153; Hôtel Dieu Hospital, Centre d'Epidémiologie Clinique Ravaud, Philippe; Université Paris Descartes, Centre d'épidémiologie clinique; INSERM U1153
Primary Subject Heading:	Pharmacology and therapeutics
Secondary Subject Heading:	Research methods, Public health
Keywords:	THERAPEUTICS, STATISTICS & RESEARCH METHODS, EPIDEMIOLOGY

SCHOLARONE™
Manuscripts

1
2
3 **Post-marketing studies for novel drugs approved by both the FDA and EMA between**
4
5 **2005 and 2010: a cross-sectional study**
6
7

8 Jean-David Zeitoun, MD, MHPM, PhD candidate ^{1,2,3}, Joseph S. Ross, MD, MHS ^{4,5,6,7},
9
10 Ignacio Atal, MSc ^{1,8}, Alexandre Vivot, MD, MPH, ^{1,8}, Nicholas S. Downing, MD ⁹, Gabriel
11
12 Baron, PhD ^{1,8,10}, Philippe Ravaud, MD, PhD ^{1,8,10,11}
13

- 14
15 
- 16 1. Centre d'Épidémiologie Clinique, Hôpital Hôtel Dieu, Assistance Publique-Hôpitaux
17 de Paris, Paris, France
 - 18 2. Gastroenterology and Nutrition, Hôpital Saint-Antoine, Assistance Publiques-
19 Hôpitaux de Paris, Paris, France
 - 20 3. Proctology, Groupe Hospitalier Diaconesses-Croix Saint-Simon, Paris, France
 - 21 4. Department of Internal Medicine, Robert Wood Johnson Foundation Clinical Scholars
22 Program, Yale School of Medicine, New Haven, Connecticut, USA
 - 23 5. Department of Internal Medicine, Section of General Internal Medicine, Yale School
24 of Medicine, New Haven, Connecticut, USA
 - 25 6. Department of Health Policy and Management, Yale School of Public Health, New
26 Haven, Connecticut, USA
 - 27 7. Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New
28 Haven, Connecticut, USA
 - 29 8. INSERM UMR 1153, Centre de Recherche Épidémiologie et Statistique Paris
30 Sorbonne Cité (CRESS), METHODS Team, Paris, France
 - 31 9. Department of Medicine, Brigham and Women's Hospital and Harvard Medical
32 School, Boston, Massachusetts
 - 33 10. Université Paris Descartes, Sorbonne Paris Cité, Paris, France
 - 34 11. Department of Epidemiology, Columbia University Mailman School of Public Health,
35 New York, New York, United States of America.
- 36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Corresponding author:** Dr. Jean-David Zeitoun, MD, MHPM, PhD candidate, Centre
4
5 d'Epidémiologie Clinique, Hôpital Hôtel Dieu, Assistance Publique-Hôpitaux de Paris, Paris,
6
7 France. E-mail: jdzeitoun@yahoo.fr
8

9 **Word count:** 3867

10
11 **Abstract:** 279

12
13 **References:** 29

14
15 **Figures:** 3

16
17
18 **Tables:** 2
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Objectives: To characterize post-marketing studies for drugs that were newly approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Design and Setting: Cross-sectional analysis of post-marketing studies registered in ClinicalTrials.gov until September 2014 for all novel drugs approved by both regulators between 2005 and 2010. Regulatory documents from both agencies were used.

Primary and secondary outcome measures: All identified post-marketing studies were classified according to planned enrolment, funding, status, and geographical location, and we determined whether studies studied the originally approved indication.

Results: Overall, 69 novel drugs approved between 2005 and 2010 were eligible for inclusion. A total of 6679 relevant post-marketing studies were identified; 5972 were interventional (89.4%). The median number of studies per drug was 55 (interquartile range [IQR]: 33-119) and median number of patients to be enrolled per study was 60 (IQR, 28-183). Industry was the primary sponsor of 2713 studies (40.6%) and was a primary or secondary sponsor in 4176 studies (62.5%). In all, 2901 studies (43.4%) were completed, 487 (7.3%) terminated, 1013 (15.2%) active yet not recruiting, 1895 (28.4%) recruiting, and 319 (4.8%) not yet recruiting. A total of 80% of studies were conducted in only one country and 84.4% took place in Europe and/or North America; 2441 (36.5%) studied another indication than the originally approved indication. Studies designed in the originally-approved indication were found to be more industry-sponsored than others 68.7% vs. 53.7%; $p < 0.0001$).

Conclusions: Post-marketing pharmaceutical research was highly variable and predominantly located in North America and Europe. Post-marketing studies were frequently designed to study indications other than the originally approved one. Although some findings were reassuring, others question the lack of coordination of post-marketing research.

Strengths and limitations of this study

This is the first study to systematically assess clinical studies performed after marketing approval by the two leading regulators, namely the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

This approach allowed us to examine a substantial number of post-marketing studies over a long time period.

However and due to registration bias, we cannot exclude that some true post-marketing studies were missed and therefore unanalyzed.

Funding: This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests: Dr. Zeitoun reports that he serves as an advisor for several consulting firms and communication companies linked with the pharmaceutical industry (Cepton, Oliver Wyman, Roland Berger, McCann Healthcare, Omnicom, Grey Healthcare, Saatchi and Saatchi Healthcare, Sudler & Hennessey, TBWA, inVentiv Health France, Havas). He also reports compensation for lectures given to manufacturer professional associations; collaboration with Mayoly-Spindler, Merck, Teva, Johnson & Johnson, and Menarini; unpaid consultancy for EY; conducting workshops funded by Amgen; and being invited to a French medical congress by AbbVie. Dr. Ross receives support through Yale University from Johnson and Johnson to develop methods of clinical trial data-sharing; from the Centers of Medicare and Medicaid Services (CMS) to develop and maintain performance measures that are used for public reporting; from Medtronic, Inc. and the US FDA to develop methods for

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

post-market surveillance of medical devices; from the Blue Cross Blue Shield Association to better understand medical technology evaluation; and from the Laura and John Arnold Foundation to support the Collaboration on Research Integrity and Transparency (CRIT) at Yale.

For peer review only

Introduction

The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are the two largest and most influential drug regulators worldwide. They tend to maintain similar premarket regulatory standards, and drug manufacturers probably tend to submit the same evidence to both as part of the premarket application process, even though we lack comparative data. Drug evaluation continues after regulatory approval, in particular through post-authorization requirements and commitments. The US FDA can use several regulatory instruments and harness various sources for post-marketing evaluation of approved drugs. Among them are the FDA Adverse Reporting System and the Sentinel System. [1] The EMA also has a set of post-authorization measures, from direct request by its dedicated committee, to specific obligations for certain drugs, all aiming at retrieving data for post-marketing assessment.[2] Yet these post-marketing clinical studies required by regulators are limited in number and are not consistently completed. [3–5] This situation raises the question of whether other studies of these drugs after regulatory approval, including those conducted by industry and independent investigators, but not to fulfill regulatory requirements, should be considered part of ongoing, continuous evaluation efforts.

Post-marketing studies are designed with different intent than are premarket trials. Their designs are not systematically submitted to regulatory agencies before initiation because many post-marketing studies are conducted by independent investigators, and their conduct is less rigorously regulated. [6] Post-marketing studies seek to evaluate safety regarding rare events, to assess the real-life effectiveness of novel drugs and to measure their long-term effects. They also permit drug evaluation in different populations, other indications for the same disease, other diseases or with different delivery systems or dosage forms. Moreover, although premarket trials are nearly exclusively sponsored by the manufacturers, post-marketing studies can be funded by manufacturers but also academic or other types of non-

1
2
3 profit institutions. Some research also suggested that a substantial proportion of post-
4
5 marketing trials, even those with results eventually published in high-impact-factor journals,
6
7 were designed for marketing purposes rather than medical interest. [7,8]
8
9

10
11 Nevertheless, post-marketing studies have considerable influence on all stakeholders,
12
13 in particular researchers, practitioners and regulators or decision makers, because they provide
14
15 cumulative evidence regarding marketed products. However, we lack an overall assessment of
16
17 post-marketing studies regarding novel drugs. Post-marketing research has been studied for
18
19 high-risk devices [9] or even for drugs, but with a focused approach: safety [10,11] or given
20
21 therapeutic areas. [12–15] Some of those studies produced reassuring results, yet others
22
23 showed inconsistencies, with gaps in knowledge regarding some issues.
24
25

26
27 Our research objective was to provide a comprehensive description of post-marketing
28
29 studies registered in ClinicalTrials.gov, a publicly-accessible clinical trial registry maintained
30
31 by the US National Institutes of Health over almost a decade for a sample of drugs approved
32
33 by both the FDA and EMA from 2005 to 2010. We aimed to characterize the total number of
34
35 studies and patients studied, targeted indications, funding origin, geographical location of
36
37 studies and status (e.g., completed or ongoing). We also sought to examine differences
38
39 between the condition of the initial label and the specific clinical condition studied in the post-
40
41 marketing studies, to assess the influence of the sponsor on the targeted indication, and to
42
43 describe supplemental indications.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Methods

Data sources and study sample

We identified all novel drugs approved between January 1, 2005 and December 31, 2010 by both the FDA and EMA through its Centralized Authorization Procedure. For the FDA, Drugs@FDA is a publicly accessible database listing relevant regulatory actions for all approved drugs. [16] For the EMA, information was accessible in the European Public Assessment Reports, which provide a summary of scientific review and list notable regulatory events for all drug submissions.[17] Generic drugs, reformulations, combination therapies and non-therapeutic agents such as radiographic dye were not included. This first search led to a sample of 71 novel drugs approved by both regulators between 2005 and 2010. Two drugs, everolimus and temsirolimus, were excluded because they were associated with an abnormally high number of post-marketing studies involving drug-eluting stents.

Drug and manufacturer characteristics

The following data were retrieved for each drug: agent type (small molecule or biologic), dates of regulatory submissions for both the FDA and EMA, orphan status according to the FDA, orphan designation from the EMA, therapeutic class according to the Anatomical Therapeutic Chemical classification, [18] initial label from both regulators, degree of novelty (first-in-class, advance-in-class, addition-to-class) as previously described in a paper from FDA officials [19] and size of the marketing-authorization holder (i.e., manufacturer). This latter information was obtained by personal communication with EMA officials (Dr. Constantinos Ziogas, Small and Medium-sized Manufacturer Office, EMA), who classified manufacturers as large pharmaceutical companies, intermediated-size companies or small- and medium-size companies according to the European Union definition based on headcount and financial turnover or balance sheet total.

Preapproval FDA pivotal trial characteristics

We obtained data for the expected length of treatment and number of patients from pivotal efficacy trials supporting FDA approvals that had been collected for a previous work. [20] In brief, acute treatment was defined as expected use < 1 month, intermediate treatment as expected use from 1 month to 2 years, and chronic treatment as expected use > 2 years.

Post-marketing studies

On September 24, 2014, we extracted all studies that were registered at ClinicalTrials.gov for each drug of our sample, regardless of dates and other details. We then excluded studies with the following characteristics: included in the FDA regulatory submission (by a manual review of Drugs@FDA), with inadequate registered status (expanded-access studies, withdrawn studies, suspended studies), and mistakenly extracted (i.e., studies actually not assessing the drug of interest). For our main analysis, we decided that all studies whose starting date had preceded the first regulatory submission (to the FDA or EMA) by 1 year or less would be classified as post-marketing studies. However, we also performed most calculations with a slightly different set of studies, namely only those whose launch started after the first regulatory approval of any agency. Trials that pertained to more than one drug in our sample were manually reviewed so as to assign them to only one drug for the sake of further statistical analysis. Clinical judgment was applied to choose the “leading” drug in each study. When we could not determine the leading drug, we used the following rules. If the study was funded by a marketing-authorization holder of one of the drugs, this drug was considered the leading drug. Otherwise, if the study involved a drug that was assessed for another indication than the originally approved indication, this drug was considered the leading drug. Finally, when no leading drug could be determined, the drug for which the last regulatory approval had been granted was considered the drug tested and was classified as the leading drug.

1
2
3 For all remaining post-marketing studies, the following data were collected: condition
4 studied, starting date, study sponsors (as a primary sponsor or a collaborator), status at the
5 date of extraction (not yet recruiting, recruiting, active yet not recruiting, enrolling by
6 invitation, completed, terminated), number and list of countries, number of centers, study
7 phase, study type (observational or interventional), randomization, and planned enrollment. In
8 addition, studies were classified as assessing the drug for its originally approved indication or
9 not, depending on the initial label. When the initial label differed between the FDA and EMA,
10 we accepted both labels as defining the originally approved indication. One of us (JDZ)
11 performed this classification after careful review of each primary label. Indications were
12 classified according to the Global Burden of Diseases classification. [21] Details of the
13 classification of post-marketing studies are provided in the Appendix.

24 25 26 27 *Supplemental indications*

28
29 We also collected approvals of supplemental indications by the FDA during the study period
30 (2005-2014) by manual review of Drugs@FDA. In the “Approval date(s) and History,
31 Letters, Labels, Reviews” section, all events designated as “efficacy-new indication” or
32 “efficacy” were reviewed and retained if deemed appropriate. Labeling revision (such as those
33 related to a modified indication or an expanded patient population) and manufacturing change
34 or addition were not included, nor were irrelevant supplemental indications. We also aimed to
35 assess the average number of patients to be enrolled in post-marketing studies to gain
36 approval of a supplemental indication. For this purpose, we took into account all patients from
37 all post-marketing studies from the start of our sample through 1 year before the issuance of
38 the supplemental indication by the FDA.

39 40 41 42 43 44 45 46 47 48 49 50 51 *Statistical analysis*

52
53 Using descriptive statistics, we characterized the premarket characteristics of the novel drugs
54 included in our sample (drugs approved by both the FDA and EMA between 2005 and 2010).
55
56
57
58
59
60

1
2
3 Next, we used descriptive statistics to characterize features of all identified post-marketing
4 studies registered at ClinicalTrials.gov for all novel drugs. We used a series of trend charts
5 representing the annual number of post-marketing studies over the life-cycle of the drugs
6 according to off- and on-condition studies. All statistical tests were two-tailed, with a type I
7 error rate of 0.05. We used SAS 9.4 (SAS Institute; Cary, NC) for all statistical analyses.
8
9
10
11
12

13 14 15 **Results**

16 *Drug sample*

17
18 Our study sample included 69 novel drugs approved between 2005 and 2010 by both the FDA
19 and EMA. In all, 51 drugs (73.9%) were small molecules and 18 (26.1%) were biologics
20 (Table 1). The FDA had granted orphan status to 18 drugs (26.1%) and the EMA an orphan
21 designation to 20 (29.0%). Among these 69 novel drugs, 24 (34.8%) were first-in-class, 24
22 (34.8%) advance-in-class and 21 (30.4%) addition-to-class. The most prevalent therapeutic
23 category was antineoplastic and immunomodulating agents (29% of all novel drugs from the
24 sample) and many drugs (68.1%) were for chronic treatment. The manufacturer was a large
25 pharmaceutical company for 44 (63.8%) of the drugs. Other details are in Table 1.
26
27
28
29
30
31
32
33
34
35
36
37

38 *Number of post-marketing trials, status and patients recruited*

39
40
41
42 Sequential exclusions leading to our final study sample of 6679 relevant post-marketing
43 studies related to all 69 novel drugs are in Supplemental Material (S1). Characteristics of all
44 post-marketing studies are in Table 2. In all, 2901 studies (43.4%) were completed, 487
45 (7.3%) terminated, 1013 (15.2%) active yet not recruiting, 1895 (28.4%) recruiting, and 319
46 (4.8%) not yet recruiting. When comparing respective numbers of post-marketing studies and
47 all clinical studies (preapproval pivotal trials and post-marketing studies), the median
48 proportion of post-marketing studies per drug was 0.96 (interquartile range [IQR] 0.93-0.98).
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

1
2
3 median of 55 studies per drug (IQR, 33-119) and mean of 96.8 studies per drug (SD 110.3).
4
5 Galsulfase, an orphan medication indicated for Mucopolysaccharidosis VI, was associated
6
7 with the lowest number of post-marketing studies (n=3) and sorafenib, a tyrosine kinase
8
9 inhibitor initially indicated for kidney cancer, with the highest number of post-marketing
10
11 studies (n=530).
12

13
14
15 Planned enrollment was also highly variable, with studies only including one patient, and one
16
17 study intending to recruit 904 585 patients (actually a prospective population-based cohort
18
19 study examining risk of congenital malformations after use of varenicline, a tobacco-use
20
21 cessation drug, in pregnant women). However, the median number of patients to be enrolled
22
23 per study was 60 (IQR 28-183). Data on the total population to be enrolled in all post-
24
25 marketing studies for a given drug was also highly varied, with a median total sample of
26
27 15 418 patients (IQR 4932-37 523). Velaglucerase alfa, an orphan medication indicated for
28
29 Gaucher disease, was associated with the lowest population size to be included in studies
30
31 (n=67), and varenicline was associated with the greatest population to be enrolled (>1 million
32
33 patients overall). Supplemental Material (S2) shows the total number of patients to be
34
35 included in post-marketing studies for each drug and proportions of industry and non-industry
36
37 funders.
38
39

40
41
42 Supplemental Material (S3) presents for each drug the number of patients included in
43
44 preapproval pivotal trials as compared with post-marketing studies. The median proportion
45
46 for the population recruited in post-marketing studies to the total population (i.e., preapproval
47
48 samples and post-marketing studies) was 0.95 (IQR 0.90-0.98). Again, alglucidase and
49
50 velaglucerase alfa were associated with the lowest number of patients in preapproval pivotal
51
52 trials. In contrast, for dabigatran, a drug initially indicated for preventing venous
53
54 thromboembolism in the European Union and to reduce the risk of stroke and systemic
55
56 embolism in patients with non-valvular atrial fibrillation in the United States, preapproval
57
58
59
60

1
2
3 pivotal trials had recruited the highest number of patients. The same figure also shows the
4
5 proportions of patients enrolled in post-marketing studies designed for the originally approved
6
7 indication, another indication and both.
8
9

10 *Trial characteristics*

11
12 Data regarding study phases are shown in Table 2; only 18.6% of identified post-marketing
13
14 studies were considered phase IV studies, whereas the most prevalent category was phase II
15
16 studies (32.6%). Data regarding randomization were missing for 2452 post-marketing studies
17
18 (36.7%). Among the remaining studies for which these data were available, 3067 were
19
20 randomized (72.6%). Other data are in Table 2.
21
22
23

24 *Sponsor*

25
26 Industry funded or partially funded nearly two-thirds of post-marketing studies. Indeed, as
27
28 shown in Table 2, industry was the primary sponsor of 2713 studies (40.6%), but when also
29
30 considering manufacturers as minority funders, industry was involved in a total of 4176
31
32 studies (62.5%). Data regarding post-marketing studies stratified by sponsorship are in Table
33
34 2. Figure 1 presents the drug sample with respect to the number of post-marketing studies and
35
36 the proportion of industry and non-industry funders for each drug. Supplemental Material (S4)
37
38 provides the same information but with a 4-year follow-up for each drug.
39
40
41
42
43
44

45 *Conditions addressed in trials*

46
47 Review of indications showed that 2441 post-marketing studies (36.5%) were launched for
48
49 another indication than the originally approved indication. Figure 2 displays the number of
50
51 non-approved indications studied in post-marketing studies for each drug of our sample, with
52
53 information regarding the more advanced phase for each newly targeted indication. When
54
55 comparing those studies with the total number of clinical studies (preapproval pivotal trials
56
57
58
59
60

1
2
3 and post-marketing studies), we found a median proportion of 0.24 (IQR, 0.09-0.4). The
4
5 median proportion for the population recruited in post-marketing studies designed for another
6
7 indication than the originally approved indication to the total population from all clinical
8
9 studies (preapproval pivotal trials and post-marketing studies) was 0.12 (IQR 0.03-0.33).
10

11
12 When analyzing the relationship between the study sponsor and the study indication, we
13
14 found that 68.7% of studies designed in the originally-approved indication were sponsored by
15
16 industry, as compared to 53.7% of studies designed in another indication ($p < 0.0001$).
17

18
19 Findings regarding planned enrollment according to the indication and stratified on funding
20
21 origin are in Supplemental Material (eTable). Regardless of the funder, post-marketing studies
22
23 targeting originally approved indications planned to enroll more patients than those studying
24
25 other indications.
26

27 28 29 *Timing*

30
31 The annual number of post-marketing studies over the life-cycle of drugs, stratified by
32
33 indication, is shown in Figure 3, exhibiting an asymmetric bell pattern, with a rapid increase
34
35 in number of post-marketing studies launched, a peak of activity within the third year after the
36
37 first regulatory submission, then a progressive decline in number of launched studies.
38

39
40 Detailed examination shows a greater proportion of studies designed for another indication
41
42 than the originally approved indication at the beginning and end of drug life-cycles.
43

44
45 Supplemental Material (S5) is based on the same data but displays information regarding
46
47 sponsors. Former post-marketing studies were predominantly funded by industry versus
48
49 academic or not-for-profit entities and this proportion increased until the second year after the
50
51 first regulatory submission. Afterwards, the proportion of non-industry funders tended to
52
53 increase over time.
54
55

56 57 58 *Location*

1
2
3 Overall, 80% of post-marketing studies were conducted in only one country. For 66 drugs, at
4 least one study was conducted in at least two countries. Sorafenib was the most concerned
5 drug in this regard, with 74 studies involving at least two countries. Data regarding locations
6 of studies for each drug are in Supplemental Material (S6). In brief, post-marketing research
7 was highly concentrated in North America (i.e., United States and/or Canada; 44.8% of all
8 post-marketing studies of the sample) and Europe (25.0%). Post-marketing studies conducted
9 in other areas represented 15.6% of all studies, and studies conducted in multiple continents
10 were few. When examining the relation between study location and study design with respect
11 to the original label, we found that studies from North America (United States and/or Canada)
12 were more frequently conducted for indications other than the originally approved indication
13 versus those located in Europe (50.4% v. 36.9%). Data from Supplemental Materials S2, S3,
14 and S6 are summarized as Tables in Supplemental Material S7.

30 *Supplemental indications*

31
32
33 During the study period, 18 novel drugs (26.1%) were associated with a least a supplemental
34 indication by the FDA: one with 4 supplemental indications, one with 3 supplemental
35 indications, 5 with two supplemental indications and 11 with one supplemental indication.

36
37
38 The mean time between the first regulatory submission and subsequent supplemental
39 indication was 4.4 years (SD 1.7; IQR 3.3-5.7). The mean number of patients to be enrolled in
40 post-marketing studies before approval of a supplemental indication was 12763.1 (SD
41 12474.3; IQR 3891.0-15856.0).

42 *Supplemental analysis*

43
44
45 Analyses of post-marketing studies shown in Table 2 were also performed when only taking
46 into account those whose launch started after the first regulatory approval. Put another way,
47 this supplemental set of analysis led us to exclude the 275 studies (see flow chart in
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Supplemental Material S1) whose starting date had preceded the first regulatory submission
4
5 by 1 year or less. Results are displayed in Supplemental Material S8, showing no obvious
6
7 difference with the main set of analysis.
8
9

10 **Discussion**

11
12
13 In our study of post-marketing clinical research studies conducted for novel drugs approved
14
15 by both the FDA and EMA between 2005 and 2010, we found high variability in number of
16
17 post-marketing studies per drug and planned enrollment per study. Indeed, the median
18
19 planned enrollment was low, 60 patients, with a median of 55 studies per drug, most of which
20
21 had not yet been completed at a minimum of 4 years after approval. Locations were
22
23 concentrated, with 72.3% of post-marketing studies conducted in North America and/or
24
25 Europe and 80% conducted in only one country. Approximately 40% of post-marketing
26
27 studies were designed for an indication other than the originally approved one, more
28
29 frequently concerning studies not involving industry funding. Overall, those findings reflect
30
31 the lack of global coordination of post-marketing research for novel drugs.
32
33
34
35

36
37 Our study has several strengths. First, we focused on a sample of drugs approved by
38
39 the two leading medical product regulators, FDA and EMA, which suggests that these drugs
40
41 are likely to be of the greatest interest and importance to clinicians worldwide. Most previous
42
43 studies focused on the FDA or EMA but rarely both. [20,22] Second, few comprehensive
44
45 studies have analyzed post-marketing research despite its undisputed public health impact. [9–
46
47 14] Most research focused on safety or was limited to a given therapeutic area, or even only
48
49 one drug. In addition, we chose a large study period, with a 6-year span for drug approvals,
50
51 and more than 10 years for the trial sample. Moreover, we followed a rigorous method for
52
53 selecting post-marketing studies, excluding clinical trials included in the FDA submission,
54
55 studies that had not been launched, studies mistakenly classified as involving the drug in
56
57
58
59
60

1
2
3 ClinicalTrials.gov and studies whose starting date was too early as compared to regulatory
4 submission. Third, we provide unique insights into the clinical research programs examining
5 non-approved drug uses. Many studies have investigated off-label prescriptions, [23,24] but
6 we used a slightly different approach. In effect, most drug labels are stringently phrased so as
7 to be rigorously aligned to pivotal trial criteria. [25] Therefore, categorizing studies according
8 to the actual off- or on-label status of the drug investigated would have led to classifying most
9 as involving off-label drug use. Put another way, the label was judged too narrow, and our
10 method offers a more significant picture for clinicians and epidemiologists. We believe that
11 our classification better reflects substantial evolution regarding the initially authorized use of
12 novel drugs.
13
14
15
16
17
18
19
20
21
22
23
24

25
26 Our findings raise several issues worthy of consideration about post-marketing
27 research. First, we showed that post-marketing research is both a heterogeneous and
28 concentrated landscape, probably linked to its loose regulation [6] and to market forces.
29 Therefore, most initiatives are at the discretion of funders, either industry or academic
30 institutions, and driven by various factors not necessarily linked to medical need or relevancy.
31 For instance, prior research has shown that many post-marketing trials were “seeding trials”,
32 designed for marketing purposes rather than scientific relevancy. [7,8] The number of post-
33 marketing studies per novel drug and planned enrollment were highly variable, but most
34 studies were conducted in only one country and North America and Europe were by far the
35 most frequent locations. Median planned enrollment was low and many studies were still not
36 completed at the time of data acquisition. These findings question the absence of steering or
37 the lack of effectiveness or incentive policies for post-marketing research. Second, almost
38 40% of post-marketing studies were designed for an indication other than the originally
39 approved indication, with non-industry trials more likely concerned. Although industry has
40 been blamed for testing their products in a too-liberal manner, [26] our findings suggest that
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 academics and other non-industry bodies might be more prone to assess authorized drugs in
4
5 innovative ways to evaluate novel indications. Third, we found that post-marketing studies
6
7 designed for the originally approved indication planned to enroll a greater number of patients
8
9 on average than those targeting novel indications. This latter finding is somewhat reassuring
10
11 because post-marketing studies for an already approved indication aim to refine knowledge
12
13 regarding the long-term effect and/or safety and should therefore include more patients than
14
15 preapproval pivotal trials.
16

17
18
19 Our study has limitations. The first may be a registration bias at ClinicalTrials.gov,
20
21 which would alter the exhaustiveness of our assessment. Some studies are not registered by
22
23 researchers [27,28] and were therefore not included in our study. Others are imperfectly
24
25 registered, with some information missing. However, ClinicalTrials.gov is widely recognized
26
27 as a benchmark registry, and recent reports showed that compliance might have improved
28
29 over time. [29] Another limitation is the definition of post-marketing studies, in that clinical
30
31 studies are designed and launched according to a continuous timing and a single threshold
32
33 might be lacking for distinguishing pre- and post-marketing trials. Therefore, we decided to
34
35 consider studies starting at most 1 year before the first regulatory submission as post-
36
37 marketing studies even though we could have made another choice. A third limitation is
38
39 related to data sources. For some data, we relied on only one of the two selected regulators.
40
41 We used such an approach for the sake of convenience and recognize that this could be
42
43 interpreted as a bias, yet to our knowledge, there are very few if any differences in data
44
45 between the two studied regulators. Therefore, this latter limitation in the methods seems
46
47 unlikely to affect our findings. Finally, we could not identify whether post-marketing trials
48
49 were relevant or useful because we did not analyze their design, endpoints, or comparators,
50
51 among other factors.
52
53
54
55
56
57
58
59
60

1
2
3 In conclusion, our research shows that post-marketing research is highly variable and
4 concentrated, with on one hand, great differences in the number of post-marketing studies per
5 drug and in planned enrollment and on the other, most studies being conducted in only one
6 country, with North America and Europe the most represented locations. Approximately 40%
7 of post-marketing studies assessed the drug for an indication other than the originally
8 approved indication, more frequently non-industry studies. Even though some of our findings
9 can be seen as reassuring, others underline the lack of global coordination of post-marketing
10 research for novel drugs despite the undisputed influence of such research.
11
12
13
14
15
16
17
18
19
20
21
22
23

24 **Contributors:** Dr. Zeitoun and Pr. Ravaud were responsible for the conception and design of
25 this work. Dr. Zeitoun drafted the manuscript and was responsible for most of the data
26 acquisition. M. Ignacio Atal was responsible for data exportation and structuration. Dr.
27 Alexandre Vivot was responsible for collection of some data and contributed to categorization
28 of studies. Dr. Nicholas Downing was responsible for some of the data acquisition. Dr.
29 Gabriel Baron conducted the statistical analysis. Drs. Ross and Ravaud provided supervision.
30 All authors participated in the analysis and interpretation of the data and critically revised the
31 manuscript for important intellectual content.
32
33
34
35
36
37
38
39
40
41
42

43 **Data sharing statement:** Data files are available from the corresponding author on
44 reasonable request.
45
46
47

48 **Acknowledgements:** The authors are grateful to EMA officials who graciously helped them
49 classify drug manufacturers. They also thank Geoffroy Beraud-Chaulet for his useful work on
50 Drugs@FDA and Elise Diard for her invaluable help on figures.
51
52
53
54

55 **References**

56
57
58
59
60

- 1 Ball R, Robb M, Anderson S, *et al*. The FDA's sentinel initiative—A comprehensive
2 approach to medical product surveillance. *Clin Pharmacol Ther* 2016;**99**:265–8.
3 doi:10.1002/cpt.320
4
- 5 European Medicines Agency. Post-authorisation procedural Q&A - Post-authorisation
6 measures: questions and answers.
7 [http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/q_and_a/q_and_a_detail_000](http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/q_and_a/q_and_a_detail_000037.jsp)
8 [037.jsp](http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/q_and_a/q_and_a_detail_000037.jsp) (accessed 8 Sep 2017).
9
- 10 United States Government Accountability Office. Drug Safety: FDA Expedites Many
11 Applications, But Data for Postapproval Oversight Need Improvement. 2015.
12 <http://www.gao.gov/products/GAO-16-192> (accessed 15 Nov 2016).
13
- 14 Fain K, Daubresse M, Alexander G. The food and drug administration amendments
15 act and postmarketing commitments. *JAMA* 2013;**310**:202–4. doi:10.1001/jama.2013.7900
16
- 17 Hoekman J, Klamer TT, Mantel-Teeuwisse AK, *et al*. Characteristics and follow-up of
18 postmarketing studies of conditionally authorized medicines in the EU. *Br J Clin Pharmacol*
19 2016;**82**:213–26. doi:10.1111/bcp.12940
20
- 21 London AJ, Kimmelman J, Carlisle B. Research ethics. Rethinking research ethics: the
22 case of postmarketing trials. *Science* 2012;**336**:544–5. doi:10.1126/science.1216086
23
- 24 Alexander GC. Seeding trials and the subordination of science. *Arch Intern Med*
25 2011;**171**:1107–8. doi:10.1001/archinternmed.2011.232
26
- 27 Barbour V, Burch D, Godlee F, *et al*. Characterisation of trials where marketing
28 purposes have been influential in study design: a descriptive study. *Trials* 2016;**17**:31.
29 doi:10.1186/s13063-015-1107-1
30
- 31 Rathi VK, Krumholz HM, Masoudi FA, *et al*. Characteristics of clinical studies
32 conducted over the total product life cycle of high-risk therapeutic medical devices receiving
33 fda premarket approval in 2010 and 2011. *JAMA* 2015;**314**:604–12.
34 doi:10.1001/jama.2015.8761
35
- 36 Reynolds RF, Lem JA, Gatto NM, *et al*. Is the large simple trial design used for
37 comparative, post-approval safety research? A review of a clinical trials registry and the
38 published literature. *Drug Saf* 2011;**34**:799–820. doi:10.2165/11593820-000000000-00000
39
- 40 Tang E, Ravaud P, Riveros C, *et al*. Comparison of serious adverse events posted at
41 ClinicalTrials.gov and published in corresponding journal articles. *BMC Med* 2015;**13**:189.
42 doi:10.1186/s12916-015-0430-4
43
- 44 Bachert C, Maurer M. Safety and efficacy of desloratadine in subjects with seasonal
45 allergic rhinitis or chronic urticaria: results of four postmarketing surveillance studies. *Clin*
46 *Drug Investig* 2010;**30**:109–22. doi:10.2165/11530930-000000000-00000
47

- 1
2
3 13 Yeh RW, Kennedy K, Spertus JA, *et al.* Do postmarketing surveillance studies
4 represent real-world populations? A comparison of patient characteristics and outcomes after
5 carotid artery stenting. *Circulation* 2011;**123**:1384–90.
6 doi:10.1161/CIRCULATIONAHA.110.991075
7
- 8
9 14 Inrig JK, Califf RM, Tasneem A, *et al.* The landscape of clinical trials in nephrology:
10 a systematic review of Clinicaltrials.gov. *Am J Kidney Dis Off J Natl Kidney Found*
11 2014;**63**:771–80. doi:10.1053/j.ajkd.2013.10.043
12
- 13 15 Endrikat J, Vogtlaender K, Dohanish S, *et al.* Safety of Gadobutrol: Results From 42
14 Clinical Phase II to IV Studies and Postmarketing Surveillance After 29 Million Applications.
15 *Invest Radiol* 2016;**51**:537–43. doi:10.1097/RLI.0000000000000270
16
- 17 16 Drugs@FDA: FDA Approved Drug Products.
18 <http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm> (accessed 15 Nov 2016).
19
- 20 17 European Medicines Agency - Find medicine - European public assessment reports.
21 http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d124 (accessed 15 Nov 2016).
22
23
24
25
- 26 18 World Health Organization (WHO) Collaborating Center for Drug Statistics
27 Methodology. ATC classification index with DDDs, 2014.
28 2014.http://www.whocc.no/atc_ddd_index/
29
- 30 19 Lanthier M, Miller KL, Nardinelli C, *et al.* An Improved Approach To Measuring
31 Drug Innovation Finds Steady Rates Of First-In-Class Pharmaceuticals, 1987–2011. *Health*
32 *Aff (Millwood)* 2013;**32**:1433–9. doi:10.1377/hlthaff.2012.0541
33
34
- 35 20 Downing NS, Aminawung JA, Shah ND, *et al.* Clinical trial evidence supporting FDA
36 approval of novel therapeutic agents, 2005-2012. *JAMA* 2014;**311**:368–77.
37 doi:10.1001/jama.2013.282034
38
- 39 21 Lozano R, Naghavi M, Foreman K, *et al.* Global and regional mortality from 235
40 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global
41 Burden of Disease Study 2010. *The Lancet* 2012;**380**:2095–128. doi:10.1016/S0140-
42 6736(12)61728-0
43
44
- 45 22 Zeitoun J-D, Lefèvre JH, Downing NS, *et al.* Regulatory review time and post-market
46 safety events for novel medicines approved by the EMA between 2001 and 2010: a cross-
47 sectional study. *Br J Clin Pharmacol* 2015;**80**:716–26. doi:10.1111/bcp.12643
48
49
- 50 23 Eguale T, Buckeridge DL, Verma A, *et al.* Association of Off-label Drug Use and
51 Adverse Drug Events in an Adult Population. *JAMA Intern Med* 2016;**176**:55–63.
52 doi:10.1001/jamainternmed.2015.6058
53
54
- 55 24 Danés I, Agustí A, Vallano A, *et al.* Outcomes of off-label drug uses in hospitals: a
56 multicentric prospective study. *Eur J Clin Pharmacol* 2014;**70**:1385–93. doi:10.1007/s00228-
57 014-1746-2
58
59
60

- 1
2
3 25 Eichler H-G, Abadie E, Breckenridge A, *et al.* Bridging the efficacy-effectiveness gap:
4 a regulator's perspective on addressing variability of drug response. *Nat Rev Drug Discov*
5 2011;**10**:495–506. doi:10.1038/nrd3501
6
- 7 26 Smith R, Gøtzsche PC, Groves T. Should journals stop publishing research funded by
8 the drug industry? *BMJ* 2014;**348**:g171.
9
- 10 27 Boccia S, Rothman KJ, Panic N, *et al.* Registration practices for observational studies
11 on ClinicalTrials.gov indicated low adherence. *J Clin Epidemiol* 2016;**70**:176–82.
12 doi:10.1016/j.jclinepi.2015.09.009
13
- 14 28 Dal-Ré R, Ross JS, Marušić A. Compliance with prospective trial registration
15 guidance remained low in high-impact journals and has implications for primary end point
16 reporting. *J Clin Epidemiol* 2016;**75**:100–7. doi:10.1016/j.jclinepi.2016.01.017
17
- 18 29 Viergever RF, Li K. Trends in global clinical trial registration: an analysis of numbers
19 of registered clinical trials in different parts of the world from 2004 to 2013. *BMJ Open*
20 2015;**5**:e008932. doi:10.1136/bmjopen-2015-008932
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Legends

Figure 1: Number of post-marketing studies and respective proportion of industry and non-industry funders.

Figure 2: Number of non-approved indications targeted in post-marketing studies for each drug of our study sample. Indications are rank-ordered on the basis of the number of post-marketing studies launched (from the greatest number of post-marketing studies on the left side of the figure to the lowest number on the right side). Color of boxes varies according to the advanced phase of the targeted indication. Indications are classified according to the Global Burden of Diseases classification. [21] Indications belonging to residual categories or health conditions not relevant to the Global Burden of Diseases were excluded and therefore are not represented in the Figure.

Figure 3: Annual number of post-marketing studies over the life-cycle of drugs, stratified by indication.

Supplemental File S1: Flow chart leading to the final study sample of 6679 relevant post-marketing studies.

Supplemental File S2: Total number of patients to be included in post-marketing studies for each drug.

Supplemental File S3: Population in preapproval pivotal trials and post-marketing studies.

Supplemental File S4: Number of post-marketing studies and respective proportion of industry and non-industry funders, with a 4-year follow-up for each drug.

1
2
3 Supplemental File S5: Annual number of post-marketing studies over the life-cycle of drugs,
4
5 stratified by sponsor.
6
7

8 Supplemental File S6: Locations of post-marketing studies.
9
10

11 Supplemental File S7: Data from S2, S3 and S6, presented as tables.
12
13

14 Supplemental File S8: Characteristics of industry and non-industry post-marketing studies
15
16 when solely taking into account those whose launch started after the first regulatory approval.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Characteristics of 69 novel drugs approved by both the FDA and EMA between 2005 and 2010 (excluding everolimus and temsirolimus).

Characteristics	n (%)
Agent type	
Small molecule	51 (73.9%)
Biologic	18 (26.1%)
Orphan status (FDA)	18 (26.1%)
Orphan designation (EMA)	20 (29.0%)
Accelerated approval (FDA)	14 (20.3%)
Therapeutic class according to the ATC classification	
Alimentary tract and metabolism	10 (14.5%)
Anti-infectives for systemic use	12 (17.4%)
Antineoplastic and immunomodulating agents	20 (29.0%)
Blood and blood forming organs	5 (7.2%)
Cardiovascular system	5 (7.2%)
Nervous system	6 (8.7%)
Other*	11 (15.9%)
Degree of novelty (according to Lanthier <i>et al</i>)	
First-in-class	24 (34.8%)
Advance-in-class	24 (34.8%)
Addition-to-class	21 (30.4%)
Size of the marketing-authorization holder	
Large pharmaceutical company	44 (63.8%)
Intermediated-size company	23 (33.3%)
Small- and medium-size company	2 (2.9%)
Premarket evidence	

Total no. of included patients	
Min/max	18/18040
Median [Q1-Q3]	923 [324-1996]
Mean (SD)	1806 (2897)
Expected length of treatment	
Acute	8 (11.6%)
Intermediate	14 (20.3%)
Chronic	47 (68.1%)

ATC, Anatomical Therapeutic Chemical

*includes dermatological, genitourinary system and sex hormones, musculoskeletal system, sensory organs, systemic hormonal preparations, excluding sex hormones, and others

Table 2. Characteristics of industry and non-industry post-marketing studies registered at ClinicalTrials.gov before September 24, 2014 for the 69 novel drugs in the study sample.

Characteristics		All (n=6679)	Industry studies (n=4176)	Non-industry studies (n=2503)
Primary sponsor	Industry	2713 (40.6%)		
	NIH	286 (4.3%)		
	US Fed	15 (0.2%)		
	Other	3665 (54.9%)		
Industry involved either as a primary sponsor or a collaborator		4176 (62.5%)		
No. of post-marketing studies per drug	Min/max	3/530		
	Median [Q1-Q3]	55 [30-119]		
	Mean (SD)	96.8 (110.3)		
Population size per drug	Min/max	67/1.05E6		
	Median [Q1-Q3]	15418 [4932-37523]		
	Mean (SD)	62748 (166644)		

Therapeutic class according to the ATC				
Alimentary tract and metabolism		832 (12.5%)	570 (68.5%)	262 (31.5%)
Anti-infectives for systemic use		828 (12.4%)	504 (60.9%)	324 (39.1%)
Antineoplastic and immunomodulating agents		3040 (45.5%)	1818 (59.8%)	1222 (40.2%)
Blood and blood forming organs		446 (6.7%)	277 (62.1%)	169 (37.9%)
Nervous system		485 (7.3%)	304 (62.7%)	181 (37.3%)
Other*		1048 (15.7%)	703 (67.1%)	345 (32.9%)
Study design with respect to primary label	Another indication than the originally approved indication	2441 (36.5%)	1310 (53.6%)	1131 (46.4%)
	Originally approved indication	3993 (59.8%)	2742 (68.7%)	1251 (31.3%)
	Both the originally approved indication and another indication	245 (3.7%)	124 (50.6%)	121 (49.3%)
Study type	Observational	707 (10.6%)	468 (66.2%)	239 (33.8%)
	Interventional	5972 (89.4%)	3708 (62.1%)	2264 (37.9%)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Randomization	Missing data	2452	1428	1024
	Yes	3067 (72.6%)	1979 (64.5%)	1088 (35.5%)
	No	1160 (27.4%)	769 (66.3%)	391 (33.7%)
Study phase	Missing data	1052	554	498
	0	34 (0.6%)	13 (38.2%)	21 (61.8%)
	I	933 (16.6%)	651 (69.8%)	282 (30.2%)
	I/II	423 (7.5%)	245 (58.0%)	178 (42.0%)
	II	1837 (32.6%)	1047 (57.0%)	790 (43.0%)
	II/III	109 (1.9%)	52 (47.7%)	57 (52.3%)
	III	1246 (22.1%)	1018 (81.7%)	228 (18.3%)
	IV	1045 (18.6%)	596 (57.0%)	449 (43.0%)
Centers	Missing data	503	428	75
	Min/max	1/1616	1/1616	1/922
	Median [Q1-Q3]	2 [1-12]	4 [1-23]	1 [1-2]
	Mean (SD)	19.9 (62.1)	26.4 (70.5)	9.8 (44.7)
Countries	Missing data	501	427	74
	Min/max	1/46	1/46	1/15
	Median [Q1-Q3]	1 [1-1]	1 [1-2]	1 [1-1]

	Mean (SD)	2.6 (4.7)	3.6 (5.8)	1.1 (0.7)
Planned enrollment	Missing data	14	9	5
	Min/max	1/904585	1/904585	1/61050
	Median [Q1-Q3]	60 [28-183]	72 [30-248]	48 [24-100]
	Mean (SD)	649.6 (12812.2)	943.8 (16167.1)	158.9 (1274.7)
Status at the time of data exportation	Not yet recruiting	319 (4.8%)	136 (42.6%)	183 (57.4%)
	Recruiting	1895 (28.4%)	886 (46.8%)	1009 (53.2%)
	Active, not recruiting	1013 (15.2%)	627 (61.9%)	386 (38.1%)
	Enrolling by invitation	64 (1.0%)	42 (65.6%)	22 (34.4%)
	Completed	2901 (43.4%)	2147 (74.0%)	754 (26.0%)
	Terminated	487 (7.3%)	338 (69.4%)	149 (30.6%)

NIH, US National Institutes of Health

*includes cardiovascular system, dermatological, genitourinary system and sex hormones, musculoskeletal system, sensory organs, systemic hormonal preparations, excluding sex hormones, and other

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1

179x153mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2

215x279mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60





Figure 3


105x51mm (300 x 300 DPI)

For peer review only

Supplemental Material 1. Sample construction of relevant post-marketing trials related to all 69 novel drugs both approved by the FDA and the EMA between 2005 and 2010, after exclusion of everolimus and temsirolimus




1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



165x133mm (300 x 300 DPI)


For peer review only



106x53mm (300 x 300 DPI)


review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




179x153mm (300 x 300 DPI)

only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



184x179mm (300 x 300 DPI)



Supplemental file S2 bis: Total number of patients to be included in post-marketing studies for each drug

Drug	Total number of patients to be included in post-marketing studies	Percentage of industry funders	Percentage of non-industry funders
Varenicline	1045002	90.8	9.2
Saxagliptin	785853	99.6	0.4
Exenatide	420256	99.3	0.7
Dabigatran	368063	93.1	6.9
Abatacept	240227	99.6	0.4
Prasugrel	128744	66.9	33.1
Sitagliptin	113824	91.8	8.2
Ranibizumab	89765	81.9	18.1
Aliskiren	76864	96.6	3.4
Sorafenib	76434	66.2	33.8
Liraglutide	73106	92.0	8.0
Lenalidomide	60805	62.8	37.2
Lapatinib	45881	77.4	22.6
Paliperidone	43024	92.6	7.4
Micafungin	41363	95.0	5.0
Entecavir	39787	65.5	34.5
Darunavir	39773	94.7	5.3
Certolizumab pegol	37523	91.6	8.4
Sunitinib	37320	70.7	29.3
Tocilizumab	36262	91.8	8.2
Denosumab	32688	90.2	9.8
Raltegravir	31285	60.8	39.2
Lacosamide	30236	93.9	6.1
Fesoterodine fumarate	23699	97.2	2.8
Panitumumab	22585	66.9	33.1
Methoxy polyethylene	22102	99.2	0.8
Ustekinumab	20873	95.5	4.5
Pazopanib	19332	54.1	45.9
Tigecycline	19322	89.3	10.7
Dasatinib	19320	72.2	27.8
Golimumab	18801	90.1	9.9
Silodosin	17591	97.5	2.5
Febuxostat	16330	88.8	11.2
Nilotinib	15657	77.0	23.0
Canakinumab	15418	98.2	1.8
Telbivudine	13590	55.6	44.4
Tolvaptan	13552	89.7	10.3
Plerixafor	13450	84.6	15.4
Ambrisentan	12300	46.1	53.9

Drug	Total number of patients to be included in post-marketing studies	Percentage of industry funders	Percentage of non-industry funders
Rotigotine	12258	96.8	3.2
Maraviroc	11957	74.3	25.7
Dronedarone	10947	62.7	37.3
Degarelix	10811	93.0	7.0
Ranolazine	10614	69.8	30.2
Deferasirox	8812	86.4	13.6
Ofatumumab	7988	84.0	16.0
Nepafenac	7627	86.2	13.8
Sapropterin	6328	90.3	9.7
Eculizumab	6065	95.5	4.5
Eltrombopag	5590	85.2	14.8
Mecasermin	5291	88.5	11.5
Ulipristal	4932	90.9	9.1
Etravirine	4881	46.4	53.6
Retapamulin	4819	95.6	4.4
Posaconazole	4391	65.1	34.9
Collagenase clostridium	3897	91.2	8.8
Anidulafungin	3819	70.8	29.2
Methylnaltrexone bromide	3581	96.6	3.4
Doripenem	3204	87.3	12.7
Nelarabine	3104	15.6	84.4
Rilonacept	2790	84.1	15.9
Asenapine maleate	2179	100.0	0.0
Romiplostim	1627	95.1	4.9
Tipranavir	1401	98.9	1.1
Rufinamide	1174	76.3	23.7
Alglucidase	803	61.4	38.6
Idursulfase	408	80.4	19.6
Galsulfase	269	100.0	0.0
Velaglucerase alfa	67	100.0	0.0

Supplemental file S3 bis: Population in preapproval pivotal trials and post-marketing studies

Drug	Population in preapproval pivotal trials	Population in post-marketing studies			Total
		Another indication	Originally-approved indication	Both in originally approved indication and in other(s) indication	
Dabigatran	18040	10896	332151	25016	368063
Prasugrel	13457	1960	126669	115	128744
Denosumab	7808	15825	16863	0	32688
Aliskiren	5663	20625	56239	0	76864
Dronedarone	4604	20	10927	0	10947
Varenicline	4198	1847	1024229	18926	1045002
Tocilizumab	4190	2201	34061	0	36262
Saxagliptin	4148	396	785457	0	785853
Febuxostat	4101	854	15476	0	16330
Liraglutide	3978	9509	62587	1010	73106
Ulipristal	3754	4012	920	0	4932
Tigecycline	2758	1339	6291	11692	19322
Methoxy polyethylene	2398	8	22094	0	22102
Golimumab	2297	1222	17579	0	18801
Asenapine maleate	2294	0	2179	0	2179
Sitagliptin	2220	2794	110745	285	113824
Doripenem	2117	267	2937	0	3204
Ustekinumab	1996	3793	17080	0	20873
Fesoterodine fumarate	1935	182	23517	0	23699
Entecavir	1814	0	39787	0	39787
Paliperidone	1665	2548	35755	4721	43024
Micafungin	1643	1105	39983	275	41363
Ranolazine	1593	2945	5773	1896	10614
Exenatide	1446	2810	417301	145	420256
Abatacept	1382	5622	234605	0	240227
Telbivudine	1367	0	13590	0	13590
Lacosamide	1308	1133	29103	0	30236
Etravirine	1203	0	4881	0	4881
Posaconazole	1202	1949	1282	1160	4391
Rotigotine	1163	4067	7671	520	12258
Tipranavir	1159	0	1365	36	1401
Ranibizumab	1139	20541	36906	32318	89765
Rufinamide	1097	288	886	0	1174
Certolizumab pegol	1088	1200	33077	3246	37523
Sildenafil	923	1339	16252	0	17591
Anidulafungin	857	792	2993	34	3819
Sorafenib	769	54317	18809	3308	76434
Raltegravir	699	83	31202	0	31285
Nepafenac	688	815	6812	0	7627
Darunavir	637	0	39773	0	39773

Drug	Population in preapproval pivotal trials	Population in post-marketing studies			Total
		Another indication	Originally-approved indication	Both in originally approved indication and in other(s) indication	
Plerixafor	623	1467	11644	339	13450
Degarelix	610	791	10020	0	10811
Deferasirox	586	153	8609	50	8812
Dasatinib	565	9267	9090	963	19320
Sunitinib	481	16462	18362	2496	37320
Panitumumab	461	5197	16874	514	22585
Maraviroc	448	560	11397	0	11957
Pazopanib	435	10363	8060	909	19332
Tolvaptan	418	12221	356	975	13552
Ambrisentan	393	715	11585	0	12300
Collagenase clostridium	374	3897	0	0	3897
Lapatinib	324	7678	37714	489	45881
Methylnaltrexone bromide	321	1359	2222	0	3581
Eltrombopag	232	2957	2533	100	5590
Retapamulin	210	267	4417	135	4819
Nilotinib	196	2431	8531	4695	15657
Lenalidomide	193	19105	39873	1827	60805
Nelarabine	190	35	3069	0	3104
Ofatumumab	154	3076	2595	2317	7988
Romiplostim	125	543	1084	0	1627
Idursulfase	96	0	408	0	408
Sapropterin	88	1133	5195	0	6328
Eculizumab	87	3861	2204	0	6065
Mecasermin	70	623	4668	0	5291
Riloncept	47	2765	25	0	2790
Galsulfase	39	0	269	0	269
Canakinumab	31	15157	261	0	15418
Velaglucerase alfa	25	0	67	0	67
Alglucidase	18	0	803	0	803

Supplemental file S6 bis: Location of post-marketing studies (sample size by location)

	Location						
	North America	Europa	Others	North America + Europa	North America + Others	Europa + Others	North America + Europa + Others
Abatacept	2267	2801	1575	1255	1715	0	9390
Alglucidase	633	5	0	83	22	20	40
Aliskiren	8269	3870	5760	5467	975	3097	33667
Ambrisentan	2128	6116	196	64	524	0	2330
Anidulafungin	1115	225	214	0	282	21	776
Asenapine maleate	950	0	0	0	0		0
Canakinumab	164	320	34	1037	0	274	13569
Certolizumab pegol	7278	5383	2401	3225	271	0	6265
Collagenase clostridium	1402	541	79	0	1286	0	400
Dabigatran	272415	47930	9639	636	0	7096	21220
Darunavir	755	2880	4076	12	1213	576	2940
Dasatinib	7476	2941	1139	768	195	484	5866
Deferasirox	1473	1023	1148	0	0	2506	2575
Degarelix	1613	5646	1522	783	0	0	1147
Denosumab	1168	4547	2692	427	0	1439	16134
Doripenem	82	195	818	52	0	0	1911
Dronedarone	480	4143	279	0	0	556	5436
Eculizumab	4683	447	52	60	92	80	463
Eltrombopag	1486	458	992	82	0	100	1059
Entecavir	807	1096	21848	4	200	184	14460
Etravirine	857	1730	570	30	671	279	536
Exenatide	371779	5876	10283	736	3323	2963	25151
Febuxostat	5473	0	1424	0	7500	0	744
Fesoterodine fumarate	4555	1231	2245	0	0	794	8210

	Location						
	North America	Europa	Others	North America + Europa	North America + Others	Europa + Others	North America + Europa + Others
Galsulfase	10	0	0	0	200	0	59
Golimumab	5459	5031	1361	706	11	120	811
Idursulfase	0	0	81	79	0	108	118
Lacosamide	1597	4167	946	1210	0	0	3281
Lapatinib	5446	9359	2989	502	1106	876	22398
Lenalidomide	22422	19825	1874	1804	1916	1972	8846
Liraglutide	15787	12960	13865	717	0	415	26892
Maraviroc	1268	1849	561	129	876	186	5698
Mecasermin	2073	3198	0	0	0	0	0
Methoxy polyethylene	340	13375	4841	0	0	2828	718
Methylnaltrexone bromide	1968	31	0	0	0	0	1462
Micafungin	37521	664	1518	0	84	619	836
Nelarabine	95	720	13	0	36	40	1900
Nepafenac	5927	227	1021	0	0	0	0
Nilotinib	1660	4393	1964	175	512	218	2882
Ofatumumab	2401	1549	20	60	14	122	3294
Paliperidone	4400	1064	10125	0	838	4753	11816
Panitumumab	2888	8858	164	375	0	0	1700
Pazopanib	5947	5436	2684	374	207	102	4518
Plerixafor	2374	850	164	0	61	46	0
Posaconazole	154	1370	126	96	0	0	600
Prasugrel	23597	42550	7015	4760	17372	0	26550
Raltegravir	3106	4949	8048	366	3156	1173	4308
Ranibizumab	17679	20576	9883	694	232	3832	33851
Ranolazine	4524	551	310	0	0	0	5102

	Location						
	North America	Europa	Others	North America + Europa	North America + Others	Europa + Others	North America + Europa + Others
Retapamulin	784	0	3000	0	508	465	60
Rilonacept	1242	30	0	0	0	244	1274
Romiplostim	280	119	76	63	62	0	175
Rotigotine	2229	3696	2553	220	601	2197	371
Rufinamide	230	278	366	75	0	0	0
Sapropterin	5120	1018	0	0	190	0	0
Saxagliptin	166072	594	13757	0	501	2670	21205
Silodosin	885	1196	1559	0	0	0	0
Sitagliptin	5577	2079	12049	164	804	3770	21728
Sorafenib	17405	13223	17312	973	2681	3230	20954
Sunitinib	8448	7676	2806	2557	2006	167	10074
Telbivudine	159	132	8934	0	308	367	1790
Tigecycline	473	1987	9632	0	1175	473	1588
Tipranavir	71	504	0	0	246	0	84
Tocilizumab	2511	17868	4033	1054	228	1270	9070
Tolvaptan	1227	304	3131	0	1300	0	4500
Ulipristal	855	2845	51	579	60	542	0
Ustekinumab	2823	2649	2004	166	0	1290	9859
Varenicline	34574	67592	6523	1307	360	0	18706
Velaglycerase alfa	0	50	17	0	0	0	0

Supplemental File S8. Characteristics of industry and non-industry post-marketing studies when only incorporating those whose launch started after the first regulatory approval.

Characteristics		All (n=6443)	Industry studies (n=4012)	Non-industry studies (n=2431)
Primary sponsor	Industry	2564 (39.8%)		
	NIH	244 (3.8%)		
	US Fed	15 (0.2%)		
	Other	3620 (56.2%)		
Industry involved either as a primary sponsor or a collaborator		4012 (62.5%)		
No. of post-marketing studies per drug	Min/max	3/498		
	Median [Q1-Q3]	51 [19-118]		
	Mean (SD)	93.4 (105.5)		
Population size per drug	Min/max	67/1.04E6		
	Median [Q1-Q3]	15212 [4819-36262]		
	Mean (SD)	61719 (166183)		

Therapeutic class according to the ATC				
Alimentary tract and metabolism		809 (12.6%)	547 (67.6%)	262 (32.4%)
Anti-infectives for systemic use		814 (12.6%)	495 (60.8%)	319 (39.2%)
Antineoplastic and immunomodulating agents		2900 (45.5%)	1742 (60.1%)	1158 (39.9%)
Blood and blood forming organs		429 (6.7%)	261 (60.8%)	168 (39.2%)
Nervous system		468 (7.3%)	288 (61.5%)	180 (38.5%)
Other*		1023 (15.9%)	679 (66.4%)	344 (33.6%)
Study design with respect to primary label	Another indication than the originally approved indication	2342 (36.4%)	1259 (53.8%)	1083 (46.2%)
	Originally approved indication	3859 (59.9%)	2631 (68.2%)	1228 (31.8%)
	Both the originally approved indication and another indication	242 (3.7%)	122 (50.4%)	120 (49.6%)
Study type	Observational	703 (10.9%)	466 (66.3%)	237 (33.7%)
	Interventional	5740 (89.1%)	3546 (61.8%)	2194 (38.2%)

Randomization	Missing data	2393	1412	981
	Yes	2950 (72.8%)	1875 (63.6%)	1075 (36.4%)
	No	1100 (27.2%)	725 (65.9%)	375 (34.1%)
Study phase	Missing data	1046	551	495
	0	33 (0.6%)	12 (36.4%)	21 (63.6%)
	I	886 (16.4%)	622 (70.2%)	264 (29.8%)
	I/II	406 (7.5%)	235 (57.9%)	171 (42.1%)
	II	1746 (32.4%)	992 (56.8%)	754 (43.2%)
	II/III	104 (1.9%)	49 (47.1%)	55 (52.9%)
	III	1180 (21.9%)	957 (81.1%)	223 (18.9%)
	IV	1042 (19.3%)	594 (57.0%)	448 (43.0%)
Centers	Missing data	468	394	74
	Min/max	1/1616	1/1616	1/922
	Median [Q1-Q3]	2 [1-12]	4 [1-23]	1 [1-2]
	Mean (SD)	19.7 (62.2)	26.1 (70.4)	9.8 (45.0)
Countries	Missing data	466	393	73
	Min/max	1/45	1/46	1/15
	Median [Q1-Q3]	1 [1-1]	1 [1-2]	1 [1-1]

	Mean (SD)	2.6 (4.6)	3.5 (5.7)	1.1 (0.7)
Planned enrollment	Missing data	14	9	5
	Min/max	1/904585	1/904585	1/61050
	Median [Q1-Q3]	60 [27-180]	70 [29-241]	48 [24-100]
	Mean (SD)	662.4 (13044.2)	966.4 (16495.6)	160.9 (1293.2)
Status at the time of data exportation	Not yet recruiting	319 (4.8%)	136 (42.6%)	183 (57.4%)
	Recruiting	1888 (29.3%)	883 (46.8%)	1005 (53.2%)
	Active, not recruiting	991 (15.4%)	619 (62.5%)	372 (37.5%)
	Enrolling by invitation	64 (1.0%)	42 (65.6%)	22 (34.4%)
	Completed	2705 (42.0%)	2000 (73.9%)	705 (26.1%)
	Terminated	476 (7.4%)	332 (69.8%)	144 (30.3%)

NIH, US National Institutes of Health

*includes cardiovascular system, dermatological, genitourinary system and sex hormones, musculoskeletal system, sensory organs, systemic hormonal preparations, excluding sex hormones, and other

eTable. Planned enrollment of post-marketing trials by industry and non-industry funding for indications targeted in trials.

Indication	Industry funding		Non-industry funding	
	No. of trials	Planned enrollment	No. of trials	Planned enrollment
Originally approved indication	2742	Median [Q1-Q3]: 100 [33-323] Mean (SD): 1322.0 (19921.8)	1251	Median [Q1-Q3]: 60 [29.5-150] Mean (SD): 230.9 (1771.2)
Other indication(s)	1310	Median [Q1-Q3]: 45 [24-128] Mean (SD): 167.7 (SD: 544.1)	1131	Median [Q1-Q3]: 40 [21-70] Mean (SD): 72.9 (148.0)
Both the originally approved indication and another indication	124	Median [Q1-Q3]: 60 [30-224] Mean (SD): 765.2 (2961.8)	121	Median [Q1-Q3]: 50 [30-120] Mean (SD): 218.1 (934.9)

Data were missing for 9 industry-funded trials and 5 other trials.